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ABSTRACT 
 
Introduction and Aims 
Barrett's esophagus (BE) is a premalignant condition to esophageal adenocarcinoma 
involving metaplasia of the esophageal epithelium. Since BE was first identified and 
described, it has been closely associated with hiatal hernia. The strength of the 
relationship has never been quantified, nor has the association, adjusted for 
confounders such as obesity and reflux, been examined. Male gender, obesity and 
reflux are well recognized risk factors for BE, however it is less certain what role 
environmental factors such as cigarette smoking play in the development of the 
condition. The association of BE with colonic tumors has also been speculated on but 
not clearly established. The aim of this thesis was to further explore the epidemiology 
of BE, specifically the relationship between BE and hiatal hernia, cigarette smoking and 
colonic tumors, through meta-analyses.  
 
Methods 
Three meta-analyses and systematic reviews were conducted, quantifying the 
relationship between BE and hiatal hernia, cigarette smoking and colonic tumors, 
respectively. Four electronic databases (Medline, PubMed, Embase, and Current 
Contents Connect) were searched for observational studies of BE patients. Pooled odds 
ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random effects 
model for the association BE with hiatal hernia, cigarette smoking and colonic tumors. 
 
Results 
A positive relationship was observed between BE and hiatal hernia, which remained 
even after adjusting for reflux. Cigarette smoking was associated with an increased risk 
of BE. This was reflected in subgroup analyses of ever-, current- and former-smokers. BE 
was also associated with colonic tumors. The relationship was observed with both 
benign adenomatous tumors as well as with colorectal cancer, though it was stronger 
for colorectal cancer. 
 
Conclusions 
The association between BE and hiatal hernia is stronger for long segment BE when 
compared with short segment BE, and it appears to be independent of reflux. BE 
patients are also more likely to have ever smoked cigarettes. BE is associated with 
colonic tumors, with the association being stronger with colorectal cancer than with 
benign lesions.  
CHAPTER	1	
 
BACKGROUND AND 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptoms suggestive of esophagitis and gastroesophageal reflux had been described in 
the medical literature since at least as early as the late 1800's,1 and the existence of 
"peptic ulcers" of the esophagus were known about by the beginning of the twentieth 
century.2 The presence of "ectopic gastric epithelium" in the esophagus had also been 
documented by Schridde3 in 1904 and Taylor4 in 1927. These were described as discrete 
round to oval lesions up to three-quarters of a inch in diameter, reminiscent of shallow 
erosions or ulcers; they were pink or red in color with centers which were slightly 
depressed below the level of the esophageal epithelium, with raised margins, and were 
typically found on the posterior aspect of the upper esophagus.3,4 However the 
recognition of what was later to become known as Barrett's esophagus (BE) as a distinct 
disease entity began in 1950 with a description of esophageal ulceration arising from a 
zone of gastric-type mucosa by the thoracic surgeon Norman Barrett.5 Allison and 
Johnstone6 used the term "lower esophagus lined with gastric mucous membrane" to 
describe the presence of gastric mucosa, including gastric glands, in the lower 
esophagus and confirmed the location of the lesion as being the esophagus itself, rather 
than stomach herniating into the thoracic cavity. Barrett subsequently used the term 
"lower esophagus lined by columnar epithelium" in his 1957 paper which more 
thoroughly described the disease.7 He differentiated this lesion from Taylor's discrete 
"ectopic islets" in that the columnar cells lining the esophagus continued upward in an 
"unbroken sheet" from the esophagogastric junction, and extended from only a few 
centimeters above the junction in some cases, to the upper esophagus in others.  
 
Currently, North American guidelines stipulate that a diagnosis of BE is made when 
columnar mucosa is identified above the gastroesophageal junction on endoscopy and 
is confirmed to contain specialized intestinal epithelia (characterized by the presence of 
goblet cells) on histological examination.8 Since 1994, BE has been classified as either 
short segment BE (SSBE) or long segment BE (LSBE), depending on the extent of 
metaplastic change observed on endoscopic examination, as measured from the 
gastroesophageal junction.9 
 
In their 1953 paper, Allison and Johnstone6 described a patient with adenocarcinoma 
which developed within the section of the esophagus lined by gastric mucosa. Both 
Allison and Johnstone6 as well as Taylor4 speculated on the "penetration" of gastric 
ectopic tissue within the esophagus and the potential for subsequent malignant 
transformation, and although early case reports10 were published linking the columnar-
lined esophagus with adenocarcinoma, it was only in the 1970's that the link was more 
definitively established.11-13 BE has since emerged as a clinically significant entity due to 
its role as the premalignant lesion of esophageal adenocarcinoma,14,15 a disease which 
although uncommon in absolute terms, has not only experienced a dramatic increase in 
incidence in recent decades,16-21 but also carries an extremely poor prognosis.22,23 As a 
result, patients with known BE are monitored by undergoing regular upper endoscopies 
with biopsy to check for dysplasia. Further study into risk factors and epidemiological 
associations of BE, which are at present not well understood, is warranted. It is against 
this background that the work contained in this thesis was embarked upon. I sought to 
examine the relationships between BE and various factors, some of which have been 
either closely associated with BE, such as hiatal hernia, and others speculated on, such 
as an association with colonic tumors and cigarette smoking. 
 
Hiatal hernia involves prolapse of elements of the abdominal cavity, most commonly 
parts of the stomach, through the esophageal hiatus of the diaphragm and into the 
thoracic cavity. It results in anatomical impairment of the esophagogastric junction, 
leading  to reflux of gastric material into the esophagus, including hydrochloric acid and 
pepsin as well as pancreatic enzymes and bile, which are thought damage the 
esophageal epithelium and contribute to the metaplasia resulting in BE.24,25 This 
mechanism has been speculated on since BE was first recognized. Barrett wondered at 
the location of the lesion and why it should always be found in the lower esophagus; he 
postulated that continued exposure to gastric juices as a result of an incompetent 
gastroesophageal sphincter could erode the normal esophageal squamous epithelium, 
which was then replaced by columnar epithelium.7 Allison and Johnstone6 reported the 
prevalence of hiatal hernia in all of the elderly patients with "lower esophagus lined 
with gastric mucous membrane" which constituted their 1953 case series. In 
agreement, Barrett also made the connection between the columnar lined esophagus 
and sliding hiatal hernia and reflux; in fact he felt that the association was strong 
enough to warrant an explicit clarification in his 1957 paper that sliding hiatal hernia 
and columnar lined esophagus were separate entities.7 Since then, the association 
between hiatal hernia and columnar or specialized intestinal metaplasia of the 
esophagus has become well established in the literature.26-28  The purpose of 
conducting a meta-analysis on the association between hiatal hernia and BE was 
twofold. Firstly, as no meta-analysis on the subject has been performed to date, we 
wanted to quantify the relationship. Secondly, we wanted to observe through subgroup 
analyses whether an association between hiatal hernia and BE remained after adjusting 
for important confounding variables. Two important risk factors for BE, namely obesity 
and gastroesophageal reflux disease (GERD)26-30 are also associated with hiatal hernia.  
The mechanism of obesity, especially central adiposity, increasing abdominal pressure 
and contributing to both hiatal hernia and reflux, and of hiatal hernia enabling reflux 
which in turn is thought to contribute to the development of BE, is very plausible. We 
thus aimed to conduct subgroup analyses looking at studies which adjusted for obesity 
and reflux, to see if the association between hiatal hernia and BE remained, 
independently of these confounders. 
 
While male gender, obesity and reflux are well recognized risk factors for BE,29 it is less 
certain what role environmental factors play in the development of BE. Smoking is a 
known risk factors for squamous cell esophageal carcinoma,31 however its association 
with adenocarcinoma, although suspected,31-34 is less well established.  Furthermore, 
cigarette smoking has not been definitely linked with an increased risk of developing BE. 
The literature results are currently mixed, with some studies showing a positive 
association,30,35-37 while others report no association.38-42 A recent analysis of 5 case 
control studies from the International Barrett's and Esophageal Adenocarcinoma 
Consortium ("BEACON")43 found a positive relationship between cigarette smoking and 
BE, thus providing a strong indicator that an association is present. To date no meta-
analysis of the relationship between cigarette smoking and BE has been performed. We 
conducted a meta-analysis examining the relationship between smoking and BE, 
specifically using subgroup analyses to determine whether a dose response exists, and 
whether the relationship changes depending on smoking status (current versus former 
versus ever smokers). 
 
The possibility of an association between BE and an increased risk of colonic tumors was 
first raised by Sontag et al in 1985.44 This is a clinically significant question because if a 
relationship is found, it carries implications in terms of screening BE patients for 
colorectal cancer (CRC). Since then, several studies have reported conflicting results. 
Although a systematic review in 199545 showed a strong association, the association is 
not well established and there is disagreement in the literature as to the impact of its 
findings. Since then, several new studies have been published reporting the prevalence 
of colonic tumors in patients with BE and therefore we considered it appropriate to 
perform a meta-analysis that also incorporated these studies. We hoped to provide 
greater insight into this possible association as well perform subgroup analyses to 
explore whether adjustment for confounding factors such as obesity (a risk factor 
common to both BE and CRC) had any impact on the association.   
 
In summary, the overarching theme of this thesis is the epidemiology of BE. Three 
meta-analyses have been conducted examining and quantifying, respectively, the 
association between BE and hiatal hernia, cigarette smoking, and colonic tumors. It is 
hoped that this work will contribute towards the body of knowledge on BE and its risk 
factors and associations.  
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CHAPTER	2	
 
HIATAL HERNIA AND THE RISK 
OF BARRETT’S ESOPHAGUS  
INTRODUCTION 
Barrett’s Esophagus (BE) is a condition in which the normal squamous esophageal lining 
is replaced by specialized or intestinal columnar epithelium.1,2 According to current 
guidelines in North America,3 BE is diagnosed when columnar mucosa is identified 
above the gastroesophageal junction on endoscopy and is confirmed to contain 
specialized intestinal epithelia (characterized by the presence of goblet cells) on 
histological examination. Since 1994, BE has been classified as either short segment BE 
(SSBE) or long segment BE (LSBE) according to the length of the metaplastic change 
observed on endoscopic examination.4 If the intestinal metaplasia extends less than 3 
cm above the gastroesophageal junction, it is termed SSBE, and if it extends 3 cm or 
more, it is termed LSBE. The prevalence of BE in the general US population is uncertain, 
due to the fact that many individuals are asymptomatic, and because diagnosis requires 
endoscopy. A study from Sweden found a prevalence of 1.6% in a random sample of 
3000 individuals from the general population.5 Among patients with gastroesophageal 
reflux disease (GERD), the prevalence of BE has been reported to be between 3% and 
15%.6,7 The clinical significance of BE is its association with an increased risk in 
developing esophageal adenocarcinoma.8,9 Although esophageal adenocarcinoma is a 
relatively uncommon disease, its incidence has been increasing in the US and other 
Western countries in recentdecades.10–15 
 
Risk factors for BE include white race, male sex, older age, obesity16 and persistent 
gastroesophageal reflux.17 Hiatal hernia has also been associated with BE. Hiatal hernia 
refers to the prolapse of elements of the abdominal cavity, most commonly parts of the 
stomach, through the esophageal hiatus of the diaphragm and into the thoracic cavity. 
The most common type is Type I, or sliding hernia, in which the lower esophageal 
sphincter and a portion of the gastric cardia herniate upwards due to a widening of the 
muscular hiatal aperture and circumferential laxity of the phrenoesophageal 
membrane.18–20 The presence of hiatal hernia results in anatomical impairment of the 
esophagogastric junction, which leads to reflux of gastric material into the esophagus. 
This includes gastric products such as hydrochloric acid and pepsin, as well as pancreatic 
enzymes and bile.17,19 It is hypothesized that chronic exposure to these substances is a 
contributing factor to the development of BE.  
 
Although individual studies have shown a higher prevalence of hiatal hernia in BE 
patients compared with non-BE GERD patients,21–23 to date no meta-analysis of the 
relationship between BE and hiatal hernia has been performed. The purpose of this 
study was to conduct a meta-analysis combining the results of studies reporting the 
prevalence of hiatal hernia in BE subjects, and thus provide a quantitative estimate of 
the increased risk of BE associated with hiatal hernia. We hypothesized that hiatal 
hernia is associated with an increased risk BE, and that we would see a stronger 
association with LSBE than with SSBE. 
 
METHODS  
Literature search strategy 
We followed the PRISMA Statement for Systematic Reviews and Meta-Analyses in 
performing our systematic review.24 A systematic search was performed by two 
reviewers (J.A. and M.T.) through four electronic databases (Medline [1950 – present], 
PubMed [1950 – present], Embase [1947 – present], and Current Contents Connect 
[1998 – present]) to 4 April 2012, for observational studies of Barrett’s esophagus 
patients, to identify relevant articles. The search used the terms “Barrett’s Esophagus” 
or “Barrett’s Esophagus” and “hiatal hernia” or “hiatus hernia”, which were searched as 
text word and as exploded medical subject headings where possible. The reference lists 
of relevant articles were also searched for appropriate studies. No language restrictions 
were used in either the search or study selection. A search for unpublished literature 
was not performed and authors were not contacted for missing data. 
 
Inclusion and exclusion criteria 
We included studies that met the following inclusion criteria: (i) BE was recognized on 
endoscopy and confirmed histologically as specialized intestinal metaplasia (SIM). 
Where studies reported on multiple subgroups, such as endoscopically suspected non-
SIM BE cases and SIM BE cases, only the SIM BE cases were included in our analyses; (ii) 
the risk point estimate was reported as an odds ratio (OR), or the data were presented 
such that an OR could be calculated; (iii) the 95% confidence interval (CI) was reported, 
or the data were presented such that the CI could be calculated; (iv) an internal control 
group was used when calculating the risk estimate; (v) the total sample size of the study 
exceeded 50 patients. We excluded studies that did not meet the inclusion criteria. 
Studies were included or excluded following consensus between three authors (J.A., 
M.T. and G.E.). 
 
Data extraction 
 We performed the data extraction via as standardized data extraction form, collecting 
information on the publication year, study design, number of cases, number of controls, 
total sample size, temporal direction of the study (prospective or retrospective), control 
groups used, population type, country, continent, economic development, case control 
matching, mean age, number of adjusted variables, the risk estimates or data used to 
calculate the risk estimates, and CIs or data used to calculate CIs, the type of BE 
investigated (SSBE or LSBE), and size of hernia. We selected only subjects with SIM to 
serve as the BE cases in our analysis. Where BE length was not stated, the study was 
included in the any length BE analysis. Adjusted ratios were extracted in preference to 
non-adjusted ratios; however, where ratios were not provided, unadjusted ORs and CIs 
were calculated. Where more than one adjusted ratio was reported, we chose the ratio 
with the highest number of adjusted variables. Where multiple risk estimates were 
available in the same study, for example, when studies reported on the risk estimates of 
different lengths of BE, or when risk estimates were reported for different control 
groups, they were included as separate risk estimates. Statistical analysis. Pooled OR 
and 95% CIs were calculated for the effect of hiatal hernia on the risk BE using a random 
effects model.25 This was performed for the association between hiatal hernia and any 
length BE. Where a study reported risk estimates for different control groups (for 
example, a GERD control group, a non-GERD control group, and a combined control 
group comprising both GERD non-GERD controls), we included the risk estimate for the 
combined control group where possible, with the separate control groups included in a 
subgroup analysis. 
 
Subgroup analyses by length of BE, adjustment of ORs, study type, and continent were 
also performed. In particular, we performed subgroup analyses by studies that adjusted 
for body mass index (BMI) and reflux, both independent risk factors for BE. Where a 
single study reported multiple ORs for different sized hernias (that is, different risk 
estimates associated with different sized hernias), we computed a pooled OR from the 
multiple ORs and used that figure as the OR for that study. We quantified the degree of 
heterogeneity using the I2 statistic, which represents the percentage of the total 
variability across studies, which is due to heterogeneity. I2 values of 25%, 50% and 75% 
corresponded to low, moderate and high degrees of heterogeneity, respectively.26 We 
performed sensitivity analyses, with individual studies excluded one at a time, when 
statistically significantly heterogeneity was detected. Publication bias was quantified 
using the Egger’s regression model,27 and if statistically significant publication bias was 
detected, the effect of bias was assessed using the fail-safe number method and the 
trim-and-fill method. The failsafe number represents the number of studies that we 
would need to have missed for our observed result to be nullified to statistical non-
significance at the P < 0.05 level. Publication bias is generally regarded as a concern if 
the fail-safe number is less than 5n + 10, with n being the number of studies included in 
the meta-analysis.28The trim-and-fill method adjusts for potential unpublished studies 
in the meta-analysis by augmenting the observed data to create a more symmetric 
funnel plot. New pooled ORs are then calculated and compared to the original pooled 
OR, and similarity between the two decreases the likelihood that publication bias 
significantly affected the meta-analysis results. Results were regarded as statistically 
significant if P < 0.05. All analyses were performed with Comprehensive Meta-analysis 
(version 2.0). 
 
RESULTS 
Study characteristics 
From 1428 studies initially identified,3321–23,29–58 met our inclusion criteria (Fig. 1). 
Selected characteristics of the included studies are presented in Table 1. The studies 
represented a variety of geographical regions, with seven studies looking at European 
populations, 13 studies examining Asian populations, 11 studies examining North 
American populations and two studies examining South American populations. In terms 
of study design, 26 studies were cross-sectional studies, and seven were case control 
studies. Sample sizes ranged from 102 to 18 766, and BE cases ranged from 9 to 1215. 
Overall, there were 4390 BE patients and 51 748 participants. 
 
Any length Barrett’s Esophagus 
Thirty-one studies comprising 3327 BE cases with a total of 47 461 individuals were 
included in the meta-analysis for any length BE. We found an increased risk of any 
length BE in patients with hiatal hernia, with pooled OR of 3.94 (95% CI, 3.02–5.13) (Fig. 
2). There was statistically significant heterogeneity (I2 = 82.03%, P < 0.001). A sensitivity 
analysis did not find any one study which contributed significantly to the heterogeneity. 
The Egger test for publication bias was significant (P = 0.0005), and this is depicted 
visually on a funnel plot (Fig. 3). However the fail-safe number was 3502 studies, and 
the trim-and-fill method showed an imputed risk estimate of OR 2.88; 95% CI, 2.23–
3.72, which was lower than the observed risk estimate but still statistically significant. 
We therefore concluded that publication bias existed, but was minimal. We performed 
subgroup analyses by different study characteristics, namely the control groups used, 
the adjustment of ORs, the continent where the study was conducted and the study 
type (Table 2). The subgroup analysis by control group showed a risk estimate for BE 
patients when compared to GERD controls of OR 3.65; 95% CI, 2.74–4.85, and OR 13.73; 
95% CI, 3.54–53.22 when compared with non-GERD controls. The pooled ORs for the 
various continents were as follows: Europe (OR 7.93; 95% CI, 3.39–18.58); North 
America (OR 3.38; 95% CI, 1.95–5.86); Asia (OR 3.84; 95% CI, 2.48–5.94); South America 
(OR 12.14; 95% CI, 3.27–45.13). A subgroup analysis looking only at the 
13studies23,29,30,34–36,38,39,42,43,56,57 which reported adjusted ORs showed an increased risk 
of any length BE associated with hiatal hernia (OR 2.99; 95% CI, 2.24–3.98). A further 
subgroup analysis looking specifically at the four studies30,38,39,57 which adjusted for BMI, 
a risk factor common to both hiatal hernia and BE, also showed an association between 
hiatal hernia and any length BE (OR 2.63; 95% CI, 1.85–3.76). There was no significant 
heterogeneity (I2 = 11.16%, P = 0.337), and no publication bias(P = 0.227). When 
stratified by adjustment for reflux, a pooled analysis of the seven studies23,29,30,34,39,42,47 
which adjusted their ORs for reflux, a major risk factor for the development of BE, the 
risk estimate remained increased (OR 3.35; 95% CI, 2.25– 4.39). There was no 
heterogeneity (I2 = 0%, P = 0.995), and no publication bias (P = 0.444). The subgroup 
analysis of the 19 studies21,31–33,35,40,41,44–46,48–55,58 which did not provide adjusted ORs also 
showed an increased risk (OR 4.26; 95% CI, 2.82–6.43). When stratifying by study type, 
the increased risk remained, though it was greater for case control studies (OR 4.38; 
95% CI, 2.91–6.61) than for cross-sectional studies (OR 3.66; 95% CI, 2.72–4.91). 
 
Short segment Barrett’s Esophagus 
 Nine studies comprising of 1019 BE cases with a total of 6357 individuals reported an 
association between hiatal hernia and SSBE and were included in the SSBE meta-
analysis. We found an increased risk of SSBE in patients with hiatal hernia, with pooled 
OR of 2.87 (95% CI, 1.75–4.70) (Fig. 4). There was statistically significant heterogeneity 
(I2 = 81.15%, P < 0.001), which became insignificant when Conio et al36 was removed on 
sensitivity analysis (I2 = 47.90%, P = 0.062), while the risk estimate was not changed 
significantly (OR 2.29; 95% CI, 1.64–3.20). The Egger test for publication bias was not 
significant (P = 0.888), and the fail-safe number was 259 studies. Subgroup analyses by 
control group, adjusting variables continent and study type were performed (Table 2). 
The subgroup analyses comparing SSBE subjects to GERD controls and non-GERD 
controls both showed an increased risk, (OR 1.86; 95% CI, 1.16–2.97) and (OR 7.93; 95% 
CI, 2.05– 30.59) respectively. When stratified by continent, the pooled risk estimates for 
Europe and North America (the only two continents with more than one study reporting 
an association between SSBE and hiatal hernia), were (OR 3.40; 95% CI, 0.53–21.89) and 
(OR2.82; 95% CI, 2.35–3.37) respectively. Subgroup analyses for adjusted ORs could not 
be performed for SSBE because of a lack of data, but the pooled risk estimate for the 
studies which did not provide adjusted ORs was OR 2.85; 95% CI, 1.43–5.67. The 
subgroup analysis by study type was as follows: case control studies (OR 5.35; 95% CI, 
1.74–16.47) and cross-sectional studies (OR 1.96; 95% CI, 1.29–2.99).Long segment 
Barrett’s Esophagus. Nine studies comprising of 648 BO cases with a total of 8233 
individuals reported an association between hiatal hernia and LSBE and were included 
in the LSBE meta analysis. We found an increased risk of LSBE in patients with hiatal 
hernia, with pooled OR of 12.67 (95% CI, 8.33–19.25) (Fig. 5). There was no significant 
heterogeneity (I2 = 31.95%, P = 0.162). The Egger test for publication bias was not 
significant (P = 0.929), and the fail-safe number was 520 studies. Subgroup analyses by 
control group, adjusting variables continent and study type were performed (Table 2). 
The subgroup analyses comparing LSBE patients with GERD controls and non- GERD 
controls both showed an increased risk, (OR 11.17; 95% CI, 6.38–19.55) and (OR 13.44; 
95% CI, 8.26–21.87) respectively. When stratified by continent, only studies from North 
America reported on the association between hiatal hernia and LSBE, and the pooled 
risk estimate was OR 13.22; 95% CI, 9.63–18.14. Looking at studies that reported 
adjusted ORs, a subgroup analysis of the three studies29,31,34 which reported adjusted 
ORs showed an increased risk of LSBO associated with hiatal hernia (OR 13.70; 95% CI, 
9.61–19.54). Two studies29,34 adjusted for reflux, and the pooled risk estimate of those 
studies showed an OR of 13.84;95% CI, 5.19–36.89. The subgroup analysis of the six 
studies21,33,36,44,45,49 which did not provide adjusted ORs also showed an increased risk 
(OR 11.97; 95% CI, 5.53–25.88). When stratified by study type, the risk estimates were 
OR 13.35; 95% CI, 9.62–18.53 for the case control subgroup and OR 11.30; 95% CI, 5.06–
25.21 for the cross-sectional subgroup. 
 
DISCUSSION 
Our systematic review and meta-analysis show what appears to be a strong relationship 
between hiatal hernia and BE, with the strength of the association being most profound 
in the LSBE group. It is plausible that hiatal hernia increases the risk of BE through 
increased esophageal exposure to gastric contents such as acid and bile,19,59,60 and 
therefore BE is more likely to be present in individuals with hiatal hernia. The idea that 
initial damage to esophageal epithelium followed by exposure to either acid alone or 
acid and bile results in metaplasia is supported by animalmodels.61–63 In addition, 
Champion et al64 and Vaezi et al59,60 found that in humans, acid and 
duodenogastroesophageal reflux occur together with possible synergistic effects and 
that such reflux is increased in patients with BE. It is therefore likely that the presence 
of hiatal hernia contributes to the development of BE through the mechanism of 
increased esophageal exposure to gastric contents. We also observed a stronger 
relationship between hiatal hernia and LSBE, compared with SSBE or any length BE. For 
the longer segment of BE to develop, the environment of increased reflux provided by 
the chronic presence of hiatal hernia may be a significant contributing factor, in which 
case hiatal hernia would be expected to be present in the majority of patients with 
LSBE. This has been found to be the case by severalinvestigators.21–23 The association of 
prolonged esophageal acid exposure and decreased esophageal sphincter pressure, 
both of which result from hiatal hernia,18,65 with BE length, have indeed been 
reported.66–68 
 
Even though we have observed strong positive relationships in our meta-analyses, we 
have identified a number of issues pertaining to our study that impact on the 
interpretation of our results. First, the results may be subject to confounders as several 
risk factors, notably age, gender and obesity, are common to both hiatal hernia and BE. 
While we have used adjusted ORs when available, some studies did not report adjusted 
ORs, and therefore our analyses include both adjusted and unadjusted ORs. To assess 
whether this has had a significant impact on our final results, we performed several 
subgroup analyses looking at studies that reported adjusted ORs. There was no 
appreciable difference in risk estimates between the subgroup analysis of studies that 
reported adjusted ORs compared with the overall result for either any length BE or 
LSBE. Obesity in particular is recognized as a risk factor common to both hiatal hernia 
and BE;16,69 however, the subgroup analysis of studies that adjusted for BMI, a measure 
of obesity, resulted in a risk estimate for any length BE, which was similar to the overall 
pooled OR. The subgroup analyses comparing BE subjects to GERD and non-GERD 
controls showed a marked increase in risk for the comparison with non-GERD controls. 
This implies that hiatal hernia is more common among GERD patients than non-GERD 
patients, and suggests a common etiology between hernia and the conditions of GERD 
and BE, which is something that is already acknowledged in the literature.20 Since GERD 
is also a significant risk factor in the development of any length BE, we conducted a 
subgroup analysis including only the studies that reported ORs adjusted for reflux, 
which showed a positive relationship (OR 3.35; 95% CI, 2.25–4.39), with the association 
being very close to that observed in the overall risk estimate for any length BE when 
including all the studies (OR 3.94). This was also observed when stratifying for studies 
reporting on LSBE, which adjusted for reflux, with the subgroup risk estimate not 
differing appreciably from the overall risk ratio for LSBE (OR 13.84 vs OR 12.67). These 
results show that even after adjusting for clinically important confounding factors, the 
relationship between BE and hiatal hernia remains significant, and this adds strength to 
the hypothesis that the relationship is a real one. 
 
Second, since both hiatal hernia and BE are recognized at endoscopy, there is the 
possibility of referral bias skewing the results towards a more positive association. This 
is because upper endoscopy is a diagnostic tool for both conditions, so they are more 
likely to be discovered incidentally in a population that is referred for this procedure.  
 
Additionally, upper endoscopy is an invasive procedure that carries risks and therefore 
ethical issues exist around performing it on members of the general population in the 
absence of any indications. The populations studied therefore necessarily consist of 
symptomatic patients in whom it is more likely that pathology will be found, so this is 
another potential source of bias affecting our results. 
 
In addition, our analysis is based on cross-sectional and case control studies, which are 
retrospective in nature, and therefore subject to the biases inherent in retrospective 
studies. If the association between hiatal hernia and BE is a real one, the temporal 
relationship is likely to be one of presence of hiatal hernia leading to the development 
of BE. In that case, the ideal study type would be one that recruited patients with hiatal 
hernia but without BE, as well as a control group who did not have hiatal hernia, and 
prospectively observed both groups for development of BE. There are, however, several 
difficulties in performing such a study. One problem is finding appropriate cases, as 
patients are usually not investigated for hiatal hernia specifically, but this is rather an 
incidental finding. Second, there is the issue of performing regular endoscopies on 
patients with hiatal hernia to observe for the development of BE, as screening 
endoscopy is not currently an indication in the management of hiatal hernia. Third, the 
choice of control group would be problematic. Once again, endoscopy is not indicated 
as a screening tool in asymptomatic individuals without a prior diagnosis of esophageal 
pathology, thus creating ethical issues around performing endoscopies to monitor for 
the development of BE in patients in whom such an intervention is not otherwise 
indicated. 
 
The size of our study was another limitation. While we identified 33 studies overall, the 
subgroup analysis were based on a smaller number of studies (nine for each of SSBE and 
LSBE). The numbers of LSBE patients were also considerably smaller, with only 648 
subjects identified, compared with 1019 SSBE patients and 3327 patients with any 
length BE. In addition, while the number of studies was not low, the number of BE cases 
in most of the studies was small. With the exception of one study,34 none of the studies 
reported on the size of the hiatal hernia. The size of the hernia could affect the strength 
of the relationship, and we would have liked to perform subgroup analyses on different 
sized hernia groups if the data were available.  
 
We observed a high degree of heterogeneity in the any length BE meta-analysis (I2 = 
82.03%, P < 0.001), which was not found on sensitivity analysis to be contributed to by 
any one study, but which we believe can be explained by the grouping together of 
patients with varying lengths of BE. Our subgroup analysis found pooled ORs of 2.87 and 
12.67 for SSBE and LSBE respectively, so we expected that an analysis of studies that 
looked simply at the presence of BE of any length would show considerable 
heterogeneity. Historically, in the early 1980s a 3cm rule introduced to prevent over 
diagnosis of BE stipulated that a minimum of3 cm of metaplasia above the observed 
gastroesophageal junction be required for the diagnosis of BE.17 This would have 
resulted in only patients with what we now classify as LSBE being diagnosed, with SSBE 
patients not being diagnosed. We had one study from the 1980s,51 which reported data 
for BE of unspecified length and was included in the any length BE analysis. Given the 
time period during which this study was conducted, the cases are likely to be what we 
now classify as LSBE. However, a sensitivity analysis excluding this study did not 
significantly alter the heterogeneity. The heterogeneity in the SSBE analysis (I2 = 
81.15%, P < 0.001) became insignificant when Conio et al36 was excluded on sensitivity 
analysis (I2 = 47.90%, P = 0.062), with the risk estimate experiencing minimal change 
(OR 2.29; 95% CI, 1.64–3.20). We were unsure as to why this study contributed to the 
heterogeneity, but it was an outlier in terms of its risk estimate when compared with 
the ORs of the other studies included in that analysis (this can be seen graphically in Fig. 
4). We speculated that some heterogeneity in this group may be due to the increased 
uncertainty in the diagnosis of SSBE as opposed to LSBE. The difficulty in precisely 
localizing and measuring the squamocolumnar junction during endoscopy, which is 
more crucial to the diagnosis of SSBE than LSBE, is well recognised.70,71 This may result 
in patients being wrongly diagnosed as having or not having SSBE. 
 
We performed an additional analysis grouping the studies by geographical location and 
study types (Table 2). There were consistent risk estimates between continents in the 
any length BE analysis, with the exception of South America, which consisted of two 
studies and found a much higher association than in the remaining continents. The 
subgroup analysis by study type showed consistently higher risk estimates in the case 
control subgroups for all lengths of BE compared with the cross-sectional subgroups. 
This raises the possibility that the case control studies are overestimating the risk and 
therefore inflating our results. However, given that our meta-analysis contained mostly 
cross sectional studies and our overall pooled ORs did not differ substantially from the 
cross-sectional subgroup risk estimates in all lengths of BE, we did not consider this to 
be a significant source of bias. 
 
The Egger test for publication bias was significant in the any length BE. However, the 
fail-safe numbers were 3502, and given our thorough search methodology, we thought 
it unlikely that so many studies would have been missed. In addition, the trim-and-fill 
method showed that the observed values were similar to the imputed values (OR 2.88 
vs OR 3.94).We therefore concluded that publication bias existed in our analysis, but 
that it was minimal.  
 
Our study had a number of strengths. The PRISMA guidelines were followed. We 
performed a thorough search through four databases with no language restrictions. 
Small studies with less than 50 total participants were excluded. We also excluded 
studies using external control groups. The use of an internal control group is recognized 
as a more statistically robust way of study design,72–74 and the exclusion of studies using 
external comparators adds rigor to our analysis. 
 
In summary, our results show that hiatal hernia is associated with an increased risk of 
BE, even after adjusting for significant confounders such as reflux and BMI. Hiatal hernia 
was associated with any length of BE; however the association was significantly greater 
with LSBE. 
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Table 1: Barrett’s esophagus studies included in the Systematic Review 
 
 
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
Abrams et al
29
 
(2008) 1a 
 
2008 
Cross-
sectional 
 
USA 
 
Patients undergoing upper endoscopy with 
histologically confirmed BE 
Patients undergoing upper endoscopy without BE Age, gender, race, indication for 
endoscopy 
9 2100 LSBE 
Abrams et al
29
 
(2008) 1b 
2008 Cross-
sectional 
USA  
Patients undergoing upper endoscopy with 
histologically confirmed BE 
Patients undergoing upper endoscopy without BE Age, gender, race, indication for 
endoscopy 
92 2100 Any Length 
BE 
Amano et 
al
30
(2006) 
2006 Cross-
sectional 
Japan  
Consecutive patients undergoing EGD with 
histologically confirmed BE 
Consecutive patients undergoing EGD for their 
annual medical check-up or for the investigation of 
their GI symptoms 
Age, gender, BMI, green tea 
consumption, fatty food consumption 
106 1668 Any length BE 
Avidan et al
22
 
(2002) 
2002 Case 
Control 
USA  
Symptomatic GERD patients with 
histologically confirmed BE 
Patients with symptomatic GERD, but with 
histologically proven absence of BE and endoscopic 
absence of erosive esophagitis, esophageal ulcer, or 
peptic stricture 
None 256 485 Any Length 
BE 
Avidan et 
al
31
(2001) 1a 
2001 Case 
Control 
USA  
Patients undergoing upper endoscopy with 
histologically confirmed BE 
Patients without symptoms of GERD and with 
normal esophageal mucosa during EGD 
Age, gender, Caucasian ethnicity, 
smoking, alcohol consumption, prior 
gastric surgery 
650 4063 SSBE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
Avidan et 
al
31
(2001) 1b 
2001 Case 
Control 
USA  
Patients undergoing upper endoscopy with 
histologically confirmed BE 
Patients without symptoms of GERD and with 
normal esophageal mucosa during EGD 
Age, gender, Caucasian ethnicity, 
smoking, alcohol consumption, prior 
gastric surgery 
366 4063 LSBE 
Banki et al
32
 
(2005) 
2005 Cross-
sectional 
USA BE patients Patients with abnormal 24-hour pH tests without BE None  
186 
 
506 
Any Length 
BE 
Byrne et al
33
 
(1999) 1a 
1999 Cross-
sectional 
UK Symptomatic patients with histologically 
confirmed BE attending clinic for open-access 
endoscopy 
Symptomatic patients without BE attending clinic for 
open-access endoscopy 
None 15 225 SSBE 
Byrne et al
33
 
(1999) 1c 
1999 Cross-
sectional 
UK Symptomatic patients with histologically 
confirmed BE attending clinic for open-access 
endoscopy 
Symptomatic patients without BE attending clinic for 
open-access endoscopy 
None 8 225 LSBE 
Byrne et al
33
 
(1999) 1b 
1999 Cross-
sectional 
UK Symptomatic patients with histologically 
confirmed BE attending clinic for open-access 
endoscopy 
Symptomatic patients without BE attending clinic for 
open-access endoscopy 
None 23 225 Any Length 
BE 
Cameron et 
al
21
 (1999) 1a 
1999 Case 
Control 
USA Patients referred for upper GI endoscopy for 
clinical indications, patients with histologically 
confirmed BE 
Consecutive patients referred for endoscopy either 
with symptoms of reflux or for non-reflux 
symptoms, without histologically confirmed BE 
None 18 167 SSBE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
Cameron et 
al
21
 (1999) 1b 
1999 Case 
Control 
USA Patients referred for upper GI endoscopy for 
clinical indications, patients with histologically 
confirmed BE 
Consecutive patients referred for endoscopy either 
with symptoms of reflux or for non-reflux 
symptoms, without histologically confirmed BE 
None 46 167 LSBE 
Cameron et 
al
21
 (1999) 1c 
1999 Case 
Control 
USA Patients referred for upper GI endoscopy for 
clinical indications, patients with histologically 
confirmed BE 
Consecutive patients referred for endoscopy either 
with symptoms of reflux or for non-reflux 
symptoms, without histologically confirmed BE 
None 64 167  
Any Length 
BE 
 
Campos et al
34
 
(2001) 1a 
2001 Cross-
sectional 
USA Patients with GERD documented by abnormal 
acid exposure on 24-hour esophageal pH 
monitoring, with histological evidence of BE 
Patients with GERD documented by abnormal acid 
exposure on 24-hour esophageal pH monitoring, 
without histological evidence of BE 
None 67 502 SSBE 
Campos et al
34
 
(2001) 1b 
2001 Cross-
sectional 
USA Patients with GERD documented by abnormal 
acid exposure on 24-hour esophageal pH 
monitoring, with histological evidence of BE 
Patients with GERD documented by abnormal acid 
exposure on 24-hour esophageal pH monitoring, 
without histological evidence of BE 
Defective LES, gender, number of 
reflux episodes 
107 502 LSBE 
Campos et al
34
  
(2001) 1c 
2001 Cross-
sectional 
USA Patients with GERD documented by abnormal 
acid exposure on 24-hour esophageal pH 
monitoring, with histological evidence of BE 
Patients with GERD documented by abnormal acid 
exposure on 24-hour esophageal pH monitoring, 
without histological evidence of BE 
Abnormal bilirubin exposure, 
defective LES, gender, defective distal 
contraction amplitude, number of 
reflux episodes longer than 5 minutes, 
duration of GERD symptoms 
174 502 Any Length 
BE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
Chacaltana et 
al
35
 (2009) 1a 
2009 Case 
Control 
Peru Patients participating in a gastric cancer 
screening campaign, with histologically 
confirmed BE 
Patients participating in a gastric cancer screening 
campaign, without symptoms of GERD and no 
esophagitis or BE on endoscopy 
Tobacco consumption, alcohol 
consumption, use of NSAIDs 
11 975 Any Length 
BE 
Chacaltana et 
al
35
 (2009) 1b 
2009 Case 
Control 
Peru Patients participating in a gastric cancer 
screening campaign, with histologically 
confirmed BE 
Patients participating in a gastric cancer screening 
campaign, with diagnosed GERD 
Tobacco consumption, alcohol 
consumption, use of NSAIDs 
11 975 Any Length 
BE 
Conio et al
36
 
(2002) 1a 
2002 Case 
Control 
Italy Patients referred for upper 
gastrointestinal endoscopy, with histologically 
confirmed BE 
Patients admitted to hospitals in the same 
catchment areas as the cases for acute, non-
neoplastic, non-GI conditions 
None 109 457 SSBE 
Conio et al
36
 
(2002) 1b 
2002 Case 
Control 
Italy Patients referred for upper 
gastrointestinal endoscopy, with histologically 
confirmed BE 
Patients admitted to hospitals in the same 
catchment areas as the cases for acute, non-
neoplastic, non-GI conditions 
None 40 457 LSBE 
Conio et al
36
 
(2002) 1c 
2002 Case 
Control 
Italy Patients referred for upper 
gastrointestinal endoscopy, with histologically 
confirmed BE 
Patients admitted to hospitals in the same 
catchment areas as the cases for acute, non-
neoplastic, non-GI conditions 
Center, gender and age 149 457 Any Length 
BE 
Conio et al
36
 
(2002) 1d 
2002 Case 
Control 
Italy Patients referred for upper 
gastrointestinal endoscopy, with histologically 
GERD controls Center, gender and age 149 457 Any Length 
BE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
confirmed BE 
Dickman et al
23
 
(2010) 
2010 Cross-
sectional 
Israel Consecutive endoscopy cases with 
histologically confirmed BE 
Consecutive endoscopy cases without histologically 
confirmed BE 
Gender 64 166 Any Length 
BE 
Grassi et al
37
 
(2006) 
2006 Cross-
sectional 
Italy Outpatients referred for endoscopy, with 
histologically confirmed BE 
Outpatients referred for endoscopy, without 
histologically confirmed BE 
None 47 224 SSBE 
Jonaitis et al
38 
(2011) 
2011 Cross-
sectional 
Lithuania Consecutive patients aged 18 years and over 
referred for upper endoscopy from primary 
and secondary settings due to upper GI 
and/or “alarm” symptoms, with histologically 
confirmed BE 
Consecutive patients aged 18 years and over 
referred for upper endoscopy from primary and 
secondary settings due to upper GI and/or “alarm” 
symptoms, without histologically confirmed BE 
Ulcer and/or stricture of esophagus, 
age, smoking (>10 cigarettes per day), 
H. pylori status, BMI, male gender 
33 4032 Any Length 
BE 
Kuo et al
39
 
(2009) 
2009 Cross-
sectional 
Taiwan Consecutive patients who underwent upper 
endoscopy for a variety of GI, with 
histologically confirmed BE 
Consecutive patients who underwent upper 
endoscopy for a variety of GI, without histologically 
confirmed BE 
Gender, age, GERD duration, smoking 
history, alcohol use, BMI, the 
presence of erosive esophagitis 
13 736 Any Length 
BE 
Lee et al
40
 
(2010) 
2010 Cross-
sectional 
Korea BE patients who had visited outpatient clinics 
to receive an upper GI endoscopy and who 
had clinical symptoms 
Patients without BE who had visited outpatient 
clinics to receive an upper GI endoscopy and who 
had clinical symptoms 
None 21 2048 Any Length 
BE 
Lord et 
al
41
(2008) 
2008 Cross-
sectional 
USA Patients with symptoms suggestive of reflux, 
with histologically confirmed BE 
Patients with symptoms suggestive of reflux, 
without histologically confirmed BE 
None 44 160 Any Length 
BE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
Mathew et al
42
 
(2011) 
2011 Cross-
sectional 
India Consecutive GERD patients with histologically 
confirmed BE 
Consecutive GERD patients without histologically 
confirmed BE 
Age, duration of symptoms, presence 
of dysphagia, presence of eructation 
25 278 Any Length 
BE 
Moons et 
al
43
(2008) 
2008 Case 
Control 
The 
Netherlands 
Caucasian patients referred for the evaluation 
of reflux-related symptoms, odynophagia or 
dysphagia, suspected extra-esophageal 
manifestations of GERD, with histologically 
confirmed BE 
Caucasian patients referred for the evaluation of 
reflux-related symptoms, odynophagia or dysphagia, 
suspected extra-esophageal manifestations of 
GERD, without histologically confirmed BE 
Age, gender, tested cytokine 
polymorphisms 
255 502 Any Length 
BE 
Nasseri-
Moghaddam 
et al
44
 (2003) 
1a 
2003 Cross-
sectional 
Iran All patients 18 years of age and older 
scheduled for upper GI endoscopy with 
histologically confirmed BE 
All patients 18 years of age and older scheduled for 
upper GI endoscopy without histologically 
confirmed BE 
None 45 269 SSBE 
Nasseri-
Moghaddam 
et al
44
 (2003) 
1b 
2003 Cross-
sectional 
Iran All patients 18 years of age and older 
scheduled for upper GI endoscopy with 
histologically confirmed BE 
All patients 18 years of age and older scheduled for 
upper GI endoscopy without histologically 
confirmed BE 
None 8 269 LSBE 
Nasseri-
Moghaddam 
et al
44
 (2003) 
1c 
2003 Cross-
sectional 
Iran All patients 18 years of age and older 
scheduled for upper GI endoscopy with 
histologically confirmed BE 
All patients 18 years of age and older scheduled for 
upper GI endoscopy without histologically 
confirmed BE 
None 68 269 Any Length 
BE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
Oberg et al
45
 
(1998) 1a 
1998 Cross-
sectional 
USA Patients with symptoms of foregut disease 
and no previous history of gastric or 
esophageal surgery, with histologically 
confirmed BE 
Patients with symptoms of foregut disease and no 
previous history of gastric or esophageal surgery, 
without histologically confirmed BE 
None 30 262 SSBE 
Oberg et al
45
 
(1998) 1b 
1998 Cross-
sectional 
USA Patients with symptoms of foregut disease 
and no previous history of gastric or 
esophageal surgery, with histologically 
confirmed BE 
Patients with symptoms of foregut disease and no 
previous history of gastric or esophageal surgery, 
without histologically confirmed BE 
None 32 262 LSBE 
Oberg et al
45
 
(1998) 1c 
1998 Cross-
sectional 
USA Patients with symptoms of foregut disease 
and no previous history of gastric or 
esophageal surgery, with histologically 
confirmed BE 
Patients with symptoms of foregut disease and no 
previous history of gastric or esophageal surgery, 
without histologically confirmed BE 
None 62 262 LSBE 
Odemis et al
46
 
(2009) 
2009 Cross-
sectional 
Turkey Consecutive patients referred for endoscopy 
for any clinical indication, with histologically 
confirmed BE 
Consecutive patients referred for endoscopy for any 
clinical indication, without histologically confirmed 
BE 
None 12 1000 Any Length 
BE 
Peng et al
47
 
(2009) 
2009 Cross-
sectional 
China Consecutive individuals aged 18-75 who 
underwent routine upper endoscopy as part 
of their regular medical examination, with 
histologically confirmed BE 
Consecutive individuals aged 18-75 who underwent 
routine upper endoscopy as part of their regular 
medical examination, without histologically 
confirmed BE 
Reflux symptoms, alcohol 
consumption 
27 2580 Any Length 
BE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
Rajendra et 
al
48
 (2004) 
2004 Cross-
sectional 
Malaysia Consecutive patients undergoing elective 
gastroscopy for predominantly upper 
abdominal or reflux complaints, with 
histologically confirmed BE 
Consecutive patients undergoing elective 
gastroscopy for predominantly upper abdominal or 
reflux complaints, without histologically confirmed 
BE 
None 123 1985 Any Length 
BE 
Rajendra et 
al
49
 (2007) 1a 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
GERD and non-GERD controls combined None 25 188 LSBE 
Rajendra et 
al
49
 (2007) 1b 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
GERD and non-GERD controls combined None 25 188 SSBE 
Rajendra et 
al
49
 (2007) 1c 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
GERD and non-GERD controls combined None 30 188 Any Length 
BE 
Rajendra et 
al
49
 (2007) 1d 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
GERD controls None 25 188 LSBE 
Rajendra et 
al
49
 (2007) 1e 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
GERD controls None 25 188 SSBE 
Rajendra et 
al
49
 (2007) 1f 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
GERD controls None 30 188 Any Length 
BE 
Rajendra et 
al
49
 (2007) 1g 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
Non-GERD controls - patients without histologically 
confirmed BE undergoing upper GI endoscopy for 
None 25 188 LSBE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
reasons other than reflux symptoms, BE 
surveillance, or any form of dyspepsia 
Rajendra et 
al
49
 (2007) 1h 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
Non-GERD controls - patients without histologically 
confirmed BE undergoing upper GI endoscopy for 
reasons other than reflux symptoms, BE 
surveillance, or any form of dyspepsia 
None 25 188 SSBE 
Rajendra et 
al
49
 (2007) 1i 
2007 Cross-
sectional 
Malaysia Patients referred to endoscopy unit, found to 
have histologically confirmed BE 
Non-GERD controls - patients without histologically 
confirmed BE undergoing upper GI endoscopy for 
reasons other than reflux symptoms, BE 
surveillance, for any form of dyspepsia 
None 30 188 Any Length 
BE 
Ringhofer et 
al
50
(2008) 
2008 Cross-
sectional 
Austria Patients investigated for symptoms of GERD 
with histologically confirmed BE 
Patients investigated for symptoms of GERD without 
histologically confirmed BE 
None 19 102 Any Length 
BE 
Sarr et al
51
 
(1985) 
1985 Cross-
sectional 
USA Patients investigated for symptoms 
compatible with GERD, including 
regurgitation, heartburn, epigastric distress, 
and dysphagia,  with histologically confirmed 
BE 
Patients investigated for symptoms compatible with 
GERD, including regurgitation, heartburn, epigastric 
distress, and dysphagia, without histologically 
confirmed BE 
None 44 362 Any Length 
BE 
Sgouros et 
al
52
(2007) 1a 
2007 Case 
Control 
Greece Patients aged 18-79 who presented to the 
clinic for investigation of heartburn and/or 
Patients with an endoscopic diagnosis of peptic 
ulcer disease who presented during the same period 
None 17 863 Any Length 
BE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
acid regurgitation, with histologically 
confirmed BE 
as cases, without symptoms typical of reflux and 
without BE 
Sgouros et 
al
52
(2007) 1b 
2007 Case 
Control 
Greece Patients aged 18-79 who presented to the 
clinic for investigation of heartburn and/or 
acid regurgitation, with histologically 
confirmed BE 
GERD patients without BE None 17 863 Any Length 
BE 
Sgouros et 
al
52
(2007) 1c 
2007 Case 
Control 
Greece Patients aged 18-79 who presented to the 
clinic for investigation of heartburn and/or 
acid regurgitation, with histologically 
confirmed BE 
GERD and non-GERD controls combined None 17 863 Any Length 
BE 
Toruner et al
53
  
(2004) 
2004 Cross-
sectional 
Turkey Consecutive dyspeptic patients, never 
previously investigated, who were referred 
for upper endoscopy in whom histologically 
confirmed BE was found 
Consecutive dyspeptic patients, never previously 
investigated, who were referred for upper 
endoscopy, without histologically confirmed BE 
None 29 395 Any Length 
BE 
Trujillo-
Benavides et 
al
54
 (2005) 
2005 Cross-
sectional 
Mexico Consecutive patients undergoing endoscopy 
in whom histologically confirmed BE was 
found 
Consecutive patients undergoing endoscopy without 
histologically confirmed BE 
None 10 109 Any Length 
BE 
Van Zanten et 
al
55
 (2006) 
2006 Cross-
sectional 
Canada Patients >18 years of with a primary 
complaint of at least 3 months of either 
Patients >18 years of with a primary complaint of at 
least 3 months of either continuous or intermittent 
None 25 1040 Any Length 
BE 
  
Authors 
 
 
Year 
 
 
Study 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
Number 
of Cases 
 
 
Total Size 
 
 
Length of 
continuous or intermittent dyspepsia of any 
severity, with histologically confirmed BE 
dyspepsia of any severity, without histologically 
confirmed BE 
Wang et al
56
 
(2008) 
2008 Cross-
sectional 
USA Patients undergoing an upper endoscopy for 
any indication, with histologically confirmed 
BE 
Patients undergoing an upper endoscopy for any 
indication, without histologically confirmed BE 
Gender, age, race, length of BE 1215 2511 Any Length 
BE 
Xiong et al
57
 
(2010) 
2010 Cross-
sectional 
China Consecutive patients aged 18-88 receiving an 
endoscopy for upper GI symptoms, with 
histologically confirmed BE 
Consecutive patients aged 18-88 receiving an 
endoscopy for upper GI symptoms, without 
histologically confirmed BE 
Age, gender, reflux esophagitis, BMI, 
heartburn 
21 2022 Any Length 
BE 
Yilmaz et al
58
 
(2006) 
 
2006 
Cross-
sectional 
Turkey Patients who underwent upper endoscopy, , 
with histologically confirmed BE 
Patients who underwent upper endoscopy, , 
without histologically confirmed BE 
None  
84 
 
18766 
Any Length 
BE 
 
Abbreviations: BE, Barrett’s esophagus; BMI, body mass index; EGD, esophagogastroduodenoscopy; GERD, gastroesophageal reflux disease; GI, gastrointestinal; LES, lower esophageal sphincter; NSAIDs, non-steroidal anti-inflammatory drugs. 
 
 
 
 
Table 2: Meta-analysis by different study characteristics 
 
Factor 
SSBE 
OR (95% CI) 
Any Length BE 
OR (95% CI) 
LSBE 
OR (95% CI) 
Control Group    
GERD Controls 1.86 (1.16-2.97) 3.65 (2.74-4.85) 11.17 (6.38-19.55) 
Non-GERD Controls 7.93 (2.05-30.59) 13.72 (3.54-53.22) 13.44 (8.26-21.87) 
Adjusted ORs    
Adjusted for any variables - 2.99 (2.24-3.96) 13.70 (9.61-19.54) 
Adjusted for BMI - 2.63 (1.85-3.76) - 
Adjusted for reflux - 3.35 (2.25-4.39) 13.84 (5.19-36.89) 
Not Adjusted 2.85 (1.43-5.67) 4.26 (2.82-6.43) 11.97 (5.53-25.88) 
Continent    
Europe 3.40 (0.53-21.89) 7.93 (3.39-18.58) - 
North America 2.82 (2.35-3.37) 3.38 (1.95-5.86) 13.22 (9.63-18.14) 
South America - 12.14 (3.27-45.13) - 
Asia - 3.84 (2.48-5.94) - 
Study type    
Case control 5.35 (1.74-16.47) 4.38 (2.91-6.61) 13.35 (9.62-18.53) 
Cross-sectional 1.96 (1.29-2.99) 3.66 (2.72-4.91) 11.30 (5.06-25.21) 
 
 
 
 
 
Figure 1: Study Selection Flowchart 
 
 
 
 
 
 
 
Figure 2: Meta-Analysis of the association between any length Barrett’s esophagus 
and hiatal hernia 
 
Test for heterogeneity I2=82.03%, p<0.001. Each study is shown by an odds ratio 
estimate with the corresponding 95% CI. 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Abrams et al (2008) 1b 3.53 2.17 5.73 0.000
Amano et al (2006) 2.29 1.85 2.84 0.000
Avidan et al (2002) 5.61 3.78 8.33 0.000
Banki et al (2005) 1.44 0.85 2.43 0.174
Byrne et al (1999) 1c 6.48 2.43 17.27 0.000
Cameron et al  (1999) 1c 11.36 4.73 27.30 0.000
Campos et al (2001) 1c 3.04 1.95 4.74 0.000
Chacaltana et al (2009) 1b 12.10 2.26 64.91 0.004
Conio et al (2002) 1c 3.90 2.52 6.04 0.000
Dickman et al (2010) 3.31 1.66 6.59 0.001
Jonaitis et al38 (2011) 5.22 1.86 14.65 0.002
Kuo et al (2009) 4.70 1.27 17.34 0.020
Lee et al (2010) 6.21 1.78 21.69 0.004
Lord et al (2008) 3.47 1.43 8.43 0.006
Mathew et al (2011) 3.95 1.24 12.57 0.020
Moons et al (2008) 2.59 1.60 4.18 0.000
Nasseri-Moghaddam et al (2003) 1c 1.91 0.98 3.72 0.057
Oberg et al (1998) 1c 3.10 1.61 5.97 0.001
Odemis et al (2009) 30.77 9.60 98.58 0.000
Peng et al (2009) 3.60 1.10 11.78 0.034
Rajendra et al (2004) 5.18 3.34 8.04 0.000
Rajendra et al (2007) 1c 12.37 5.49 27.88 0.000
Ringhofer et al (2008) 6.78 2.31 19.89 0.000
Sarr et al (1985) 13.41 6.55 27.46 0.000
Sgouros et al (2007) 1c 6.35 1.44 27.98 0.015
Toruner et al  (2004) 3.49 1.57 7.74 0.002
Trujillo-Benavides et al (2005) 12.21 1.49 100.11 0.020
Van Zanten et al (2006) 1.34 0.55 3.26 0.518
Wang et al (2008) 1.46 1.22 1.74 0.000
Xiong et al (2010) 2.42 0.31 19.05 0.401
Yilmaz et al (2006) 0.76 0.28 2.07 0.592
3.94 3.02 5.13 0.000
0.01 0.1 1 10 100
Protective Harmful
Figure 3: Funnel plot to assess publication bias 
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Figure 4: Meta-Analysis of the association between short segment Barrett’s 
esophagus and hiatal hernia 
 
 Test for heterogeneity I2 = 81.15%, p < 0.001. Each study is shown by an odds ratio 
estimate with the corresponding 95% CI. 
 
 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Avidan et al (2001) 1b 2.96 2.43 3.61 0.000
Byrne et al (1999) 1a 3.43 1.17 10.07 0.025
Cameron et al (1999) 1a 3.63 1.20 10.96 0.022
Campos et al (2001) 1a 2.16 1.20 3.87 0.010
Conio et al (2002) 1a 13.92 7.79 24.88 0.000
Grassi et al (2006) 0.79 0.35 1.77 0.567
Nasseri-Moghaddam et al (2003) 1a 1.87 0.93 3.77 0.080
Oberg et al (1998) 1a 1.81 0.81 4.05 0.149
Rajendra et al (2007) 1b 4.31 1.48 12.56 0.007
2.87 1.75 4.70 0.000
0.01 0.1 1 10 100
Protective Harmful
Figure 5: Meta-Analysis of the association between long segment Barrett’s esophagus 
and hiatal hernia 
 
Test for heterogeneity I2=31.95%, p = 0.162. Each study is shown by an odds ratio estimate 
with the corresponding 95% CI. 
 
 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Abrams et al (2008) 1a 12.81 2.61 62.94 0.002
Avidan et al (2001) 1a 13.68 9.35 20.02 0.000
Byrne et al (1999) 1b 38.71 2.20 681.36 0.012
Cameron et al  (1999) 1b 30.70 7.06 133.52 0.000
Campos et al (2001) 1b 14.51 4.18 50.36 0.000
Conio et al (2002) 1b 10.05 4.91 20.57 0.000
Nasseri-Moghaddam et al (2003) 1b 2.16 0.44 10.58 0.342
Oberg et al (1998) 1b 6.33 2.14 18.72 0.001
Rajendra et al (2007) 1a 30.50 11.03 84.35 0.000
12.67 8.33 19.25 0.000
0.01 0.1 1 10 100
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CHAPTER	3	
 
CIGARETTE SMOKING AND THE 
RISK OF BARRETT’S 
ESOPHAGUS 
 
  
INTRODUCTION 
Barrett’s Esophagus (BE) involves the replacement of the normal squamousesophageal 
lining by specialized or intestinal columnar epithelium.
1,2
 The main clinical significance 
of BE is its association with an increased risk of developing esophageal 
adenocarcinoma,
3
 which although historically an uncommon disease, has been 
experiencing a dramatic increase in incidence in the US and other Western countries 
over recent decades.
4-7
 The prevalence of BE in the general population is uncertain 
mainly because BE subjects are often asymptomatic and therefore do not present for 
diagnostic endoscopy. However, a study from Sweden found a prevalence of 1.6% in a 
random sample of 3000 individuals from the general population.
8
 Among patients with 
gastroesophageal reflux disease (GERD), which is a common complaint, the prevalence 
of BE has been reported to be between 3 and 15%.
9, 10
 
 
Risk factors for BE include white race, male sex, older age, obesity
11
 and GERD.
12 
While 
cigarette smoking is a well-recognized risk factor in the development of esophageal 
squamous cell carcinoma,
13
 and has been associated with esophageal adenocarcinoma 
in some studies,
14
 it has not been definitely linked with an increased risk of developing 
BE. The literature results are currently mixed, with some studies showing a positive 
association,
8,11,15-17
 while others report no association.
18-22
 A recent analysis of 5 case 
control studies from the International Barrett's and Esophageal Adenocarcinoma 
Consortium ("BEACON") consortium
23
 found a positive relationship between cigarette 
smoking and BE, thus providing a strong indicator that an association is present. 
 
With a rapidly increasing incidence of adenocarcinoma, which carries a poor 
prognosis,
24
 the importance of identifying modifiable risk factors for its precursor 
lesion, BE, is obvious in terms of patient education of preventative measures. To 
date no meta-analysis of the relationship between cigarette smoking and BE has 
been performed. To confirm the relationship between smoking and BE found in 
the recent BEACON consortium analysis,
23
 we conducted a meta-analysis 
combining the results of studies reporting the prevalence of cigarette smoking in 
BE subjects, and thus provided a quantitative estimate of the increased risk of BE 
associated with smoking. 
 
MATERIALS AND METHODS 
Search strategy 
We followed the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) 
guidelines
25
 in conducting our meta-analysis. A systematic search was conducted 
through four electronic databases (Medline [1950 – present], PubMed [1950 – present], 
Embase [1947 – present], and Current Contents Connect [1998 – present]) to April 18, 
2012, for observational studies of BE patients, to identify relevant articles. The terms 
"Barrett’s Esophagus" or "Barrett’s esophagus" and "smoking" or "tobacco" or 
"cigarettes" were searched as text word and as exploded medical subject headings 
where possible. The reference lists of relevant articles were manually searched for 
appropriate studies. No language restrictions were used in either the search or study 
selection. A search for unpublished literature was not performed and authors were not 
contacted for missing data. 
 Inclusion criteria 
Studies were included if they met the following inclusion criteria: (i) studies used a case 
control, nested case control, cross-sectional or cohort study design; (ii) BE was 
recognized on endoscopy and confirmed histologically as specialized intestinal 
metaplasia (SIM); (iii) the prevalence of cigarette smoking in BE cases and controls 
groups was examined; (iv) the risk point estimate was reported as an odds ratio (OR), or 
the data was presented such that an odds ratio could be calculated; (v) the 95% 
confidence interval (CI) was reported, or the data was presented such that the 
confidence interval could be calculated; (vi) an internal control group was used when 
calculating the risk estimate. 
 
We excluded studies that did not meet the inclusion criteria. Specifically, studies were 
excluded for the following reasons: (i) studies looked at endoscopically-suspected BE 
patients, and not subjects with SIM;
26-30
 (ii) data on prevalence of smoking in BE cases 
and controls not reported;
31,32
 (iii) article was part of a cohort study from which more 
recent, updated data was available;
33
 (iv) study used endoscopically-suspected BE 
subjects as controls.
34
 Studies were included or excluded following consensus between 
two authors (J.A. and G.E.). 
 
Data extraction 
We performed the data extraction via a standardized data extraction form, collecting 
information on the publication year, study design, number of cases, number of controls, 
total sample size, temporal direction (prospective or retrospective), control groups 
used, country, continent, case control matching, mean age, number of adjusted 
variables, the risk estimates or data used to calculate the risk estimates, confidence 
intervals or data used to calculate confidence intervals, smoking status (current, former 
or ever smoker), the number of pack-years smoked, and length of BE. We selected only 
subjects with SIM to serve as the BE cases in our analysis; if different sub-groups were 
reported, such as endoscopically suspected non-SIM BE patients and SIM BE patients, 
only the SIM BE patient data was used. Where BE length was not stated, the study was 
categorized as "any length BE". Adjusted ratios were extracted in preference to non 
adjusted ratios, however, where ratios were not provided, unadjusted odds ratios and 
confidence intervals were calculated. Where more than one adjusted ratio was 
reported, the ratio with the highest number of adjusted variables was selected. Where 
multiple risk estimates were available in the same study, for example when risk 
estimates were reported for different control groups, they were included as separate 
risk estimates. The different risk estimates from the same study were denoted by the 
study name followed by sequential alphabetical letters. For example, the study by 
Anderson et al
18
 provided risk estimates for ever smokers, former smokers, current 
smokers, smoking < 15 pack years, and smoking > 40 pack years. These different risk 
estimates were referred to in the tables as Anderson et al a
18
, Anderson et al b
18
, 
Anderson et al c
18
 , Anderson et al d
18
 and Anderson et al e
18
, respectively. We excluded 
data on subjects who smoked pipe, cigar or chewed tobacco, so as to better examine 
the effect on subjects of smoking tobacco in cigarette form, compared to those who did 
not use tobacco. 
 
Statistical analysis 
Pooled odds ratios (OR) and 95% confidence intervals (CI) for the effect of smoking on 
the risk BE were calculated using a random effects model.
35
 Separate risk estimates 
were calculated comparing BE cases with different control groups, namely a non-GERD 
control group and a GERD control group. The comparison between BE patients and 
GERD and non-GERD patients was done for two reasons. Firstly, many of the individual 
studies themselves used either GERD or non-GERD controls. To eliminate a layer of 
heterogeneity on the control groups, we maintained this grouping in comparing GERD 
and non-GERD patients as two separate control groups. Secondly, since GERD is itself a 
risk factor for BE
12
, we wanted to see if there existed a relationship between BE and 
smoking that was independent of GERD. The non-GERD control group included both 
population-based controls, as well as subjects who were received an upper endoscopy 
for any indication, but who were not diagnosed with GERD, or the diagnosis of GERD 
was not specified. We thus also calculated risk estimates using the sub-set of the non-
GERD controls representing population-based controls as the control group. Exposure 
variables relating to cigarette smoking were ever-smokers, current smokers and former 
smokers. The smoking exposure was either for current smokers, former smokers, or 
ever-smokers – the “ever-smoking” group included both current and/or former 
smokers, and was included as a subgroup analysis to examine if an association between 
having ever smoked and BE existed, and also to compare this any association found with 
BE in current smokers and former smokers. From each study that reported pack-years 
smoked, we grouped all the risk estimates for the lowest reported number of pack years 
smoked in the "lowest pack-years" group, and the risk estimates for the highest 
reported number of pack years smoked in the "highest pack-years" group, and 
calculated pooled ORs and 95% CIs for each of these groups. Due to the smaller number 
of studies reporting on number of pack-years smoked, these analyses were performed 
using the non-GERD and GERD controls together, comparing BE cases with "all 
controls". 
 
The degree of heterogeneity was quantified using the I2 statistic, which represents the 
percentage of the total variability across studies which is due to heterogeneity rather 
than chance alone. I
2
 values of 25%, 50% and 75% corresponded to low, moderate and 
high degrees of heterogeneity, respectively.
36
 Subgroup analyses by adjustment for 
confounding variables, study type, length of BE and continent were also performed 
using the ever-smoking as the exposure variable. Where heterogeneity was present, a 
sensitivity analysis was performed to determine the influence of each study on the 
pooled risk estimates by excluding individual studies one at a time. 
 
Publication bias was quantified using the Egger’s regression model,
37
 and if statistically 
significant publication bias was detected, the effect of bias was assessed using the fail-
safe number method and the trim-and-fill method. The fail-safe number represents the 
number of studies that we would need to have missed for our observed result to be 
nullified to statistical non-significance at the P <0.05 level.
38
 The trim-and-fill method 
adjusts for potential unpublished studies in the meta-analysis by calculating new pooled 
ORs based on a more symmetric funnel plot which are then compared to the original 
pooled OR. Similarity between the two decreases the likelihood that publication bias 
significantly affected the meta-analysis results. Results were regarded as statistically 
significant if the two-tailed P < 0.05. All analyses were performed with Comprehensive 
Meta-analysis (version 2.0). 
 
RESULTS 
Search results and study characteristics 
From 811 studies initially identified, 39
8,11,15-22,39-67 
met our inclusion criteria (Figure 1). 
Selected characteristics of the included studies are presented in Table 1. The studies 
represented a variety of geographical regions, with 17 North American studies, 11 
European studies, seven Asian studies, two Australian studies, and one study each from 
Africa and South America. Study sizes ranged from 100 to 27 813, and BE cases ranged 
from 8 to 1677. Overall, there were 7069 BE patients and 132 168 participants. 
 
Quantitative data synthesis 
Table 2 contains the risk estimates calculated for the association of BE with different 
smoking exposures using the non-GERD, population-based and GERD control groups, as 
well as the combined "all controls" group as comparisons. 27 studies
8,11,17,18,20-22,39,44,45,47-
55,57,60,62-67 
comprising 5965 BE cases with a total of 125 534 individuals were included in 
the meta-analysis for comparing BE cases with non-GERD controls. BE patients were 
more likely to have ever smoked compared with non-GERD controls (OR 1.44) (Figure 
2). There was statistically significant heterogeneity (I
2 
= 62%, P = 0.002) and a sensitivity 
analysis did not identify any one study which contributed significantly to the 
heterogeneity. The Egger test for publication bias was significant (P = 0.027). The fail-
safe number was 122 studies, and the trim-and-fill method showed an imputed risk 
estimate of OR 1.31 (95% CI, 1.07-1.60). There was also an increased risk of BE 
associated with being current smoker (OR 1.33) and a former smoker (OR 1.51). In the 
former smoker analysis, Smith et al
17 
was a major contributor to heterogeneity, with the 
heterogeneity being reduced and becoming statistically insignificant with removal of 
the study (I
2 
= 49%, P = 0.057), while the pooled risk estimate was only minimally 
affected (OR 1.40, 95% CI, 1.15-1.72). When stratified by adjustment for any 
confounding factors, pooled risk estimates of the seven included studies
11,48-50,55,63 
revealed that being an ever-smoker was associated with an increased risk of BE (OR 
1.90). The heterogeneity became statistically insignificant on sensitivity analysis with 
the omission of Jacobson et al,
49
 (I
2 
= 44%, P = 0.111), while the pooled risk estimate 
was increased (OR 2.13; 95% CI, 1.52-2.98). The sub-group analysis of the six
11,48 50,55 
studies which adjusted for measures of obesity showed an increased risk of BE 
associated with ever smoking (OR 1.72). There was heterogeneity which again was 
reduced and became statistically insignificant when Jacobson et al
49
 was removed (I
2 
= 
22%, P= 0.273), while the pooled risk estimate was increased (OR 1.91; 95% CI, 1.46-
2.51). As Jacobson et al
49
 only studied a female population, and so its removal also 
yielded the risk estimate for stratification by adjustment for age and gender. The sub 
group analyses by study type, length of BE and continent are shown instable 2. 
 
19 studies
8,11,17,18,20-22,39,40,44,45,47,48,50,53-55,65,67
 compared 4829 BE patients with population-
based controls, a sub-set of the non-GERD controls. We observed an increased risk of BE 
associated with being an ever-smoker (OR 1.42), a current smoker (OR 1.22), as well as 
a former smoker (OR 1.57) when comparing BE subjects with population-based controls. 
Heterogeneity was present in these analyses and a sensitivity analysis did not reveal any 
single study which was a significant contributor to the heterogeneity. When stratifying 
for the four studies
11,48,50,55 
which adjusted for any confounding variables, there was an 
increased risk of BE associated with being an ever-smoker (OR 1.96). The same four 
studies adjusted for measures of obesity (BMI or waist-to-hip ratio), age and gender, so 
no further subgroup analysis was performed. The sub-group analyses by continent are 
shown in Table 2. 
 
There were 20 studies
15-17,19,21,22,39,41-43,46,54-56,58,59,61-63,67 
comprising 3850 BE cases with a 
total of 40 559 individuals which compared BE cases with GERD controls. We did not 
observe a statistically significant risk for BE in ever-smokers (Figure 3). However, the risk 
was increased for current smokers (OR 1.52) and former smokers (OR 1.39). The 
subgroup analysis of the three studies
16,55,63 
which adjusted for any confounding 
variables showed that ever-smoking was associated with an increased risk of BE, with an 
OR of 1.96 and high heterogeneity. Rubenstein et al
63
 was a significant contributor to 
the heterogeneity; omitting the study reduced the heterogeneity to a moderate level (I
2 
= 57%, P = 0.128), however the pooled risk estimate was likewise affected (OR 1.46; 
95% CI, 0.99-2.15). Since Rubenstein et al
63
 was also the only one of the three studies 
which did not adjust for both age and gender, removal of this study resulted in the risk 
estimate for age and gender-adjustment. The sub-group analyses by continent are 
shown in Table 2. 
 
Eight studies
11,16-18,48,55,65,67 
comprising of 1788 BE cases with a total of 9736 individuals 
reported an association between the number of pack-years smoked and BE and were 
included in the dose-response meta-analyses, presented in Table 3. Both lowest and 
highest pack year groups were associated with an increased risk of BE, the risk being 
greater for the higher consumption group. A subgroup analysis of the "highest pack-
years" group including the six studies
11,16-18,65,67 
which adjusted for measure of obesity 
found a further increase in risk (OR 1.70; 95% CI, 1.37-2.10). 
 DISCUSSION 
Our meta-analysis shows a positive relationship between cigarette smoking and BE, 
confirming the findings of Cook et al.
23
 Our studies used both GERD controls and non- 
GERD controls as the comparator groups, which enabled us to calculate pooled ORs 
comparing the risk estimates associated with smoking in BE patients with different 
control groups. The strongest associations were found when comparing BE patients 
with population-based controls, and this was true both for the overall analyses, as well 
as the subgroup analyses. While the associations were positive, the weakest 
associations between smoking and BE were found when comparing BE patients with 
GERD controls. This suggests that smoking might be implicated in the etiology of both 
GERD and BE, and indeed studies have shown that smoking may contribute to 
gastroesophageal reflux by lowering lower esophageal sphincter tone.
68, 69
 
 
We recognized that our results may be influenced by confounders, and while we have 
used adjusted ORs when available, some studies did not report adjusted ORs. Sub-group 
analyses performed for the ever-smokers exposure group found the relationships to 
increase in strength for all comparator groups when adjusting for confounders. This 
suggest that the presence of confounders have not biased our overall results. 
 
A stronger relationship with BE was observed in former smokers when compared with 
current or ever-smokers across all the comparator group analyses. This is interesting, 
and is something which was noted by other investigators,
11,54,65
 who speculated on 
increased health-seeking behavior among former smokers leading to an increased 
likelihood of BE diagnosis, or increased susceptibility of current smokers to acquire 
Helicobacter pylori,
65
 which is thought to be protective of BE,
70
 as possible explanations 
for the phenomenon. To this we add our hypothesis that former smokers may 
experience weight gain which may in turn increase their risk for developing GERD and 
BE, and hence the increased risk associated with BE in this exposure group. It has been 
documented that smoking cessation is often followed by weight gain,
71,72
 and that 
central adiposity and obesity are risk factors for the development of BE.
11
 While 
plausible, this explanation is still speculative in nature, and no established explanation 
currently exists. 
 
A possible dose response was suggested by our results, with a stronger association 
found between smoking and BE in the "highest pack-year" group, compared with the 
"lowest pack-year" group (OR 1.53 versus OR 1.41). Since it has been found that heavy 
smokers tend to have increased body weight compared with light smokers,
73,74
 we 
conducted a subgroup analysis for the studies in the "highest pack-year" group which 
adjusted for measures of obesity. The risk was actually increased in the "highest pack-
year" group when adjusting for obesity, suggesting that obesity is not confounding the 
results in the "highest pack-year" group. The presence of a dose response would 
suggest a real association between smoking and the risk of developing BE, however, 
there is considerable overlap of the 95% CIs between the lowest and highest pack-year 
group analyses, and so we cannot comment with confidence about the presence of a 
trend from lowest to highest levels of consumption. 
 
When stratifying by study design, we observed the positive relationship between 
smoking and BE to be maintained. While the pooled risk estimate for ever smokers in 
the case control subgroup analysis was predictably greater (OR 1.68) than for ever 
smokers in the cohort subgroup analysis (OR 1.20), the pooled risk estimate for the 
cohort subgroup analysis was statistically significant and approximated the risk 
estimates for ever- and current smokers in the main analyses. We therefore concluded 
that study design was not a significant source of bias in our results. A moderate to high 
degree of heterogeneity was observed in many of our analyses and often, the source of 
heterogeneity was not identified on sensitivity analysis. Smith et al
17
 was a significant 
contributor to heterogeneity in the former smokers, BE patients versus non-GERD 
controls analysis. It was not clear exactly why this study in particular contributed to 
heterogeneity, though it did have a relatively high proportion of former smokers in the 
BE group (49%) compared to other studies. Jacobson et al
49
 and Rubenstein et al
63
 also 
contributed to heterogeneity in subgroup analyses, and while it was not completely 
clear as to why this should be, they were the only studies among the studies which 
adjusted for confounding variables not to adjust for both age and gender. Jacobson et 
al
49
 was based on a female cohort, so this explains their inability to adjust for gender. 
We thought that one possible explanation for the observed heterogeneity could be the 
grouping together of different lengths of BE. A minority of studies actually reported risk 
estimates for SSBE or LSBE, and after we performed subgroup analyses based on BE 
length, heterogeneity was still present in the LSBE analysis for the ever-smokers 
exposure group, so this made it less likely that the heterogeneity in the overall analyses 
being mainly due to the grouping together of BE of differing length. There was 
insufficient data to calculate a pooled OR for ever-smokers by SSBE. However, since only 
a few studies reported on BE length, an analysis based on such a small number may not 
be powered sufficiently to draw solid conclusions from.  
 
Publication bias was present in the analysis for ever-smokers comparing BE patients to 
non-GERD controls. While the Egger test for publication bias was significant (P = 0.027), 
the fail-safe number was 122 studies, and given our thorough search strategy, and the 
fact that the analysis itself only consisted of 27 studies, we thought it unlikely that 122 
studies would have been missed. In addition, the trim-and-fill method showed an 
imputed risk estimate which was statistically significant and similar to our observed risk 
estimate. We therefore concluded that publication bias existed, but was minimal. 
 
Our study had a number of strengths. The MOOSE guidelines were followed. A thorough 
search was performed through four databases and we imposed no language 
restrictions. Studies which used external control groups were excluded. The use of an 
internal control group is recognized as a more statistically robust way of study design, 
and the exclusion of studies using external comparators adds rigor to our analysis. This 
is the first meta-analysis on the association between cigarette smoking and BE, and it 
combines a 39 studies with 7069 BE patients, making it the largest study on the subject 
to date. Cook et al
23
 have also found a positive relationship between smoking and BE 
from an analysis of the BEACON data; our results confirm this from an analysis of a 
larger number of studies, which included two prospective cohort studies.  
 
Our study also had several limitations. It was subject to the bias present in the 
individual studies and the possible presence of confounders. Most of our studies 
followed a case control study design, and were therefore subject to recall and selection 
bias which are inherent to retrospective studies. In this particular instance however, we 
did not think that recall bias with regards to smoking was a significant bias, as it has 
been shown that recall of tobacco use is reliable among study participants.
75
 The use of 
population-based controls in many of the studies also reduced possible selection bias 
on the results, as population-based controls were chosen at random from established 
registries or surgery lists. Also, while we identified 39 studies overall and the total 
number of BE patients was relatively large, our analyses included small studies. Some of 
these included only eight or 11 BE patients, and it is questionable as to whether they 
had the statistical power to generate meaningful results. In addition, our analysis only 
included two prospective cohort studies. 
 
In summary, this meta-analysis has found evidence that smoking is a risk factor for the 
development of BE. Positive relationships exist between different smoking exposure 
variables and BE and the association remained, and increased in strength, after 
adjusting for significant confounders. Since this represents one of the few potentially 
modifiable risk factors for BE, we believe that it is an important finding in terms of 
patient counseling and BE prevention. 
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Table 1: Barrett’s Esophagus Studies included in the Systematic Review 
 
 
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Anderson et al 
(2007) a 
18
 
2007 Case 
control 
Ireland Non-GERD 
controls 
62.4 for BE 
cases, 63 for 
controls 
None Age and 
gender 
224 711 LSBE Ever smoker 
Anderson et al 
(2007) b 
18
 
2007 Case 
control 
Ireland Non-GERD 
controls 
62.4 for BE 
cases, 63 for 
controls 
Gender, age at interview date, BMI 5 years prior to the interview date, 
alcohol intake (grams), years of full-time education and job type (manual, 
non-manual), gastro-esophageal reflux 
Age and 
gender 
224 711 LSBE Former smoker 
Anderson et al 
(2007) c 
18
 
2007 Case 
control 
Ireland Non-GERD 
controls 
62.4 for BE 
cases, 63 for 
controls 
Gender, age at interview date, BMI 5 years prior to the interview date, 
alcohol intake (grams), years of full-time education and job type (manual, 
non-manual), gastro-esophageal reflux 
Age and 
gender 
224 711 LSBE Current smoker 
Anderson et al 
(2007) d 
18
 
2007 Case 
control 
Ireland Non-GERD 
controls 
62.4 for BE 
cases, 63 for 
controls 
Gender, age at interview date, BMI 5 years prior to the interview date, 
alcohol intake (grams), years of full-time education and job type (manual, 
non-manual), gastro-esophageal reflux 
Age and 
gender 
224 711 LSBE < 15 pack years 
Anderson et al 
(2007) e 
18
 
2007 Case 
control 
Ireland Non-GERD 
controls 
62.4 for BE 
cases, 63 for 
controls 
sex, age at interview date, BMI 5 years prior to the interview date, alcohol 
intake (grams), years of full-time education and job type (manual, non-
manual), gastro-esophageal reflux 
Age and 
gender 
224 711 LSBE > 40 pack years 
Avidan et al 
(2001) a 
20
 
2001 Case 
control 
USA Non-GERD 
controls 
61 for BE cases, 
59 for controls 
Age, gender, ethnicity, alcohol consumption, hiatus hernia, gastric surgery  650 4063 SSBE Current smoker 
Avidan et al 
(2001) b 
20
 
2001 Case 
control 
USA Non-GERD 
controls 
61 for BE cases, 
59 for controls 
Age, gender, ethnicity, alcohol consumption, hiatus hernia, gastric surgery  366 4063 LSBE Current smoker 
Avidan et al 
(2002) 
15
 
2002 Case 
control 
USA GERD 
controls 
59.3 for BE 
cases, 57.7 for 
controls 
None  256 485 Any length Current smoker 
Casson et al 
(2006) a 
39
 
2006 Case 
control 
Canada GERD 
controls 
 None  125 402 Any length Ever smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Casson et al 
(2006) b 
39
 
2006 Case 
control 
Canada Non-GERD 
controls 
 None  125 402 Any length Ever smoker 
Chacaltana et al 
(2009) a 
21
 
2009 Case 
control 
Peru GERD 
controls 
52.2 for BE 
cases, 51.3 for 
controls 
None  11 2273 Any length Current smoker 
Chacaltana et al 
(2009) b 
21
 
2009 Case 
control 
Peru Non-GERD 
controls 
52.2 for BE 
cases, 50.5 for 
controls 
Hiatal hernia, NSAID consumption, alcohol consumption  11 2273 Any length Current smoker 
Conio et al 
(2002) 
40
 
2002 Case 
control 
Italy Non-GERD 
controls 
58.5 for BE 
cases, 61.1 for 
controls 
Geographic center, gender and age  149 600 Amy 
length 
Current smoker 
Dhawan et al 
(2001) 
41
 
2001 Cross-
sectional 
India GERD 
controls 
47 for BE cases, 
36 for controls 
None  16 271 Any length Current smoker 
di Martino et al 
(2007) 
42
 
2007 Case 
control 
UK GERD 
controls 
65 for BE cases, 
56 for controls 
None  200 584 Any length Ever smoker 
Edelstein et al 
(2007) a 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio Age and 
gender 
193 404 Any length Ever smoker 
Edelstein et al 
(2007) b 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio Age and 
gender 
193 404 Any length Former smoker 
Edelstein et al 
(2007) c 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio Age and 
gender 
193 404 Any length Current smoker 
Edelstein et al 
(2007) d 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio Age and 
gender 
54 404 LSBE Ever smoker 
Edelstein et al 
(2007) e 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio Age and 
gender 
54 404 LSBE Former smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Edelstein et al 
(2007) f 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
193 611 LSBE Ever smoker 
Edelstein et al 
(2007) g 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
193 611 Any length < 13.5 pack-years 
 
Edelstein et al 
(2007) h 
11
 
2007 Case 
control 
USA Non-GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
193 611 Any length > 13.5 pack-years 
Edelstein et al 
(2007) i 
11
 
2007 Case 
control 
USA GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
193 611 Any length < 13.5 pack-years 
 
Edelstein et al 
(2007) j 
11
 
2007 Case 
control 
USA GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
193 611 Any length > 13.5 pack-years 
Edelstein et al 
(2009) a 
16
 
2009 Case 
control 
USA GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
193 611 Any length Former smoker 
Edelstein et al 
(2009) b 
16
 
2009 Case 
control 
USA GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
193 611 Any length Current smoker 
Edelstein et al 
(2009) c 
16
 
2009 Case 
control 
USA GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
54 611 LSBE Ever smoker 
Edelstein et al 
(2009) d 
16
 
2009 Case 
control 
USA GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
54 611 LSBE Former smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Edelstein et al 
(2009) e 
16
 
2009 Case 
control 
USA GERD 
controls 
 Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
54 611 LSBE Current smoker 
Eloubeidi et al 
(2001) 
43
 
2001 Case 
control 
USA GERD 
controls 
64 for BE cases, 
57 for controls 
None Age and 
gender 
88 176 Any length Current smoker 
Ferrandez et al 
(2006) a 
44
 
2006 Case 
control 
Spain Non-GERD 
controls 
53.96 for BE 
cases, 53.37 for 
controls 
None Age and 
gender 
104 317 Any length Current smoker 
Ferrandez et al 
(2006) b 
44
 
2006 Case 
control 
Spain Non-GERD 
controls 
53.96 for BE 
cases, 53.37 for 
controls 
None Age and 
gender 
104 317 Any length Ex-smoker 
Ferrandez et al 
(2006) c 
44
 
2006 Case 
control 
Spain Non-GERD 
controls 
53.96 for BE 
cases, 53.37 for 
controls 
Age, gender, waist-to-hip ratio, and clinic month of 
biopsy and 
clinic 
104 317 Any length Ever smoker 
Fouad et al 
(2009) 
19
 
2009 Case 
control 
Egypt GERD 
controls 
48.3 for BE 
cases, 37.6 for 
controls 
None  73 1000 Any length Current smoker 
Gerson et al 
(2002) a  
45
 
2002 Case 
control 
USA Non-GERD 
controls 
61 None  27 110 Any length Current smoker 
Gerson et al 
(2002) b 
45
 
2002 Case 
control 
USA Non-GERD 
controls 
61 None  27 110 Any length Ex-smoker > 10 
pack years 
Gerson et al 
(2007) 
46
 
2007 Case 
control 
USA GERD 
controls 
58.5 for BE 
cases, 54.5 for 
controls 
Age, gender, race, GERD duration, income level, alcohol consumption, 
family history 
 165 751 Any length Current smoker 
Gerson et al 
(2009) 
47
 
2009 Cross-
sectional 
USA Non-GERD 
controls 
60 for BE cases, 
49 for controls 
None  8 126 Any length Current smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Ibiebele et al 
(2011) a 
48
 
2011 Case 
control 
Australia Non-GERD 
controls 
 Age, gender, education, BMI 1 year previously, frequency of heartburn or 
acid reflux 10 years prior to diagnosis, lifetime alcohol intake, NSAID use, 
and total energy intake 
Age and 
gender 
266 944 Any length Ever smoker 
Ibiebele et al 
(2011) b 
48
 
2011 Case 
control 
Australia Non-GERD 
controls 
 Age, gender, education, BMI 1 year previously, frequency of heartburn or 
acid reflux 10 years prior to diagnosis, lifetime alcohol intake, NSAID use, 
and total energy intake 
Age and 
gender 
266 944 Any length < 14.9 pack-years 
 
Ibiebele et al 
(2011) c 
48
 
2011 Case 
control 
Australia Non-GERD 
controls 
 Age, gender, education, BMI 1 year previously, frequency of heartburn or 
acid reflux 10 years prior to diagnosis, lifetime alcohol intake, NSAID use, 
and total energy intake 
Age and 
gender 
266 944 Any length ≥ 30 pack-years 
 
Jacobson et al 
(2011) a 
49
 
2011 Cohort USA Non-GERD 
controls 
 Year of endoscopy, age, BMI, physical activity, daily caloric intake/day, 
alcohol consumption, hormone use 
 377 20863 Any length Ever smoker 
Jacobson et al 
(2011) b 
49
 
2011 Cohort USA Non-GERD 
controls 
 Year of endoscopy, age, BMI, physical activity, daily caloric intake/day, 
alcohol consumption, hormone use 
 377 20863 Any length Former smoker 
Jacobson et al 
(2011) c 
49
 
2011 Cohort USA Non-GERD 
controls 
 Year of endoscopy, age, BMI, physical activity, daily caloric intake/day, 
alcohol consumption, hormone use 
 377 20863 Any length Current smoker 
Johansson et al 
(2007) a 
50
 
2007 Case 
control 
Sweden Non-GERD 
controls 
60.3 for BE 
cases, 51.4 for 
controls 
Age, gender, reflux symptoms, BMI, H.pylori status, alcohol consumption  21 764 Any length Ever smoker 
Johansson et al 
(2007) b 
50
 
2007 Case 
control 
Sweden Non-GERD 
controls 
60.3 for BE 
cases, 61.8 for 
controls 
Age, gender, reflux symptoms, BMI, H.pylori status, alcohol consumption Age and 
gender 
21 764 Any length Ever smoker 
Johnston et al 
(1996) 
51
 
1996 Cross-
sectional 
USA Non-GERD 
controls 
52 for BE cases, 
48 for controls 
None  16 170 Any length Current smoker 
Jonaitis et al 
(2011) 
52
 
2011 Case 
control 
Lithuania Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Ulcer and/or stricture of esophagus, age, hiatal hernia, H. Pylori status, 
BMI, gender 
 33 4032 Any length Current smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Kicinski et al 
(2009) a 
53
 
2009 Case 
control 
Poland Non-GERD 
controls 
55.9 for BE 
cases, 54.3 for 
controls 
None  36 111 Any length Current smoker 
Kicinski et al 
(2009) b 
53
 
2009 Case 
control 
Poland Non-GERD 
controls 
55.9 for BE 
cases, 54.2 for 
controls 
None  36 111 Any length Current smoker 
Kubo et al 
(2009) 1a 
54
 
2009 Case 
control 
USA GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, race (white vs non-white), gender, location of diagnosis, fruit and 
vegetable intake, H.pylori status, income, and education 
Gender, age 
and 
geographical 
region 
320 953 Any length Former smoker 
Kubo et al 
(2009) 1b 
54
 
2009 Case 
control 
USA GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, race (white vs non-white), gender, location of diagnosis, fruit and 
vegetable intake, H.pylori status, income, and education 
Gender, age 
and 
geographical 
region 
320 953 Any length Current smoker 
Kubo et al 
(2009) 1c 
54
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, race (white vs non-white), gender, location of diagnosis, fruit and 
vegetable intake, H.pylori status, income, and education 
Gender, age 
and 
geographical 
region 
320 953 Any length Former smoker 
Kubo et al 
(2009) 1d 
54
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, race (white vs non-white), gender, location of diagnosis, fruit and 
vegetable intake, H.pylori status, income, and education 
Gender, age 
and 
geographical 
region 
320 953 Any length Current smoker 
Kubo et al 
(2009) 2a 
55
 
2009 Case 
control 
USA GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, race (white vs. non-white), gender, and education Gender, age 
and 
geographical 
region 
320 953 Any length Ever vs never 
Kubo et al 
(2009) 2b 
55
 
2009 Case 
control 
USA GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
Age, race (white vs. non-white), gender, and education Gender, age 
and 
geographical 
320 953 Any length Current smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
population region 
Kubo et al 
(2009) 2c 
55
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, race, gender, and education, BMI, recent alcohol use (number of 
drinks/week), aspirin or NSAID use, total caloric intake, a comorbidity index 
(the DxCg score), H. pylori status, geographic location 
Gender, age 
and 
geographical 
region 
320 953 Any length Ever smoker 
Kubo et al 
(2009) 2d 
55
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
 Gender, age 
and 
geographical 
region 
320 953 Any length Current smoker 
Kubo et al 
(2009) 2e 
55
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, gender, race, and education Gender, age 
and 
geographical 
region 
320 953 LSBE Ever smoker 
Kubo et al 
(2009) 2f 
55
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, gender, race, and education Gender, age 
and 
geographical 
region 
320 953 SSBE Ever smoker 
Kubo et al 
(2009) 2g 
55
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, gender, race, and education Gender, age 
and 
geographical 
region 
320 953 Any length < 10 pack-years 
Kubo et al 
(2009) 2h 
55
 
2009 Case 
control 
USA GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, gender, race, and education Gender, age 
and 
geographical 
region 
320 953 Any length < 10 pack-years 
Kubo et al 
(2009) 2i 
55
 
2009 Case 
control 
USA Non-GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
Age, gender, race, and education Gender, age 
and 
geographical 
320 953 Any length > 50 pack-years 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
population region 
Kubo et al 
(2009) 2j 
55
 
2009 Case 
control 
USA GERD 
controls 
62.7 for BE 
cases, 45.13 for 
the total 
population 
Age, gender, race, and education Gender, age 
and 
geographical 
region 
320 953 Any length > 50 pack-years 
Kuo et al (2010) 
56
 
2010 Cross-
sectional 
Taiwan GERD 
controls 
49.2 for BE 
cases, 50.5 for 
the total 
population 
Age, gender, duration of GERD, hiatal hernia, reflux esophagitis, alcohol 
consumption, BMI 
 13 736 Any length Current smoker 
Lam et al (2008) 
57
 
2008 Case 
control 
USA Non-GERD 
controls 
55 for BE cases, 
55 for controls 
Age, gender, ethnicity, alcohol consumption  56 5293 Any length Current smoker 
Mathew et al 
(2011) 
58
 
2011 Case 
control 
India GERD 
controls 
50.04 for BE 
cases, 
None  25 303 Any length Current smoker 
Olliver et al 
(2005) 
59
 
2005 Case 
control 
UK GERD 
controls 
63 for BE cases, 
52 for controls 
None  50 147 Any length Ever smoker 
Park et al 
(2009) 
60
 
2009 Cross-
sectional 
South Korea Non-GERD 
controls 
 Age, gender, NSAID use, BMI, hiatal hernia, cholesterol, alcohol 
consumption, reflux esophagitis 
 215 23565 Any length Current smoker 
Rajendra et al 
(2004) 
61
 
2004 Case 
Control 
Malaysia GERD 
controls 
51.1 for BE 
cases, 60.6 for 
controls 
None  123 1985 Any length Current smoker 
Rajendra et al 
(2007) a 
62
 
2007 Case 
control 
Malaysia GERD 
controls 
55.1 for BE 
cases, 52.7 for 
controls 
None  25 188 SSBE Current smoker 
Rajendra et al 
(2007) b 
62
 
2007 Case 
control 
Malaysia GERD 
controls 
58.7 for BE 
cases. 52.7 for 
controls 
None  30 188 LSBE Current smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Rajendra et al 
(2007) c 
62
 
2007 Case 
control 
Malaysia GERD 
controls 
 None  55 188 Any length Current smoker 
Rajendra et al 
(2007) d 
62
 
2007 Case 
control 
Malaysia Non-GERD 
controls 
55.1 for BE 
cases, 50.6 for 
controls 
None  25 188 SSBE Current smoker 
Rajendra et al 
(2007) e 
62
 
2007 Case 
control 
Malaysia Non-GERD 
controls 
58.7 for BE 
cases, 50.6 for 
controls 
None  30 188 LSBE Current smoker 
Rajendra et al 
(2007) f 
62
 
2007 Case 
control 
Malaysia Non-GERD 
controls 
 None  55 188 Any length Current smoker 
Ronkainen et al 
(2005) a 
8
 
2005 Cross-
sectional 
Sweden Non-GERD 
controls 
56.9 for BE 
cases, 53.5 for 
controls 
Age and gender  16 1000 Any length Current smoker 
Ronkainen et al 
(2005) b 
8
 
2005 Cross-
sectional 
Sweden Non-GERD 
controls 
56 for BE cases, 
53.5 for 
controls 
Age and gender  11 1000 SSBE Current smoker 
Rubenstein et al 
(2008) a 
63
 
2008 Case 
control 
USA GERD 
controls 
60 for BE cases, 
60 for controls 
Age and veteran/civilian status Age and 
veteran/civili
an status 
45 100 Any length Ever smoker 
Rubenstein et al 
(2008) b 
63
 
2008 Case 
control 
USA Non-GERD 
controls 
60 for BE cases, 
60 for controls 
Age and veteran/civilian status Age and 
veteran/civili
an status 
50 100 Any length Ever smoker 
Siersema et al 
(2006) 
64
 
2006 Case 
control 
USA Non-GERD 
controls 
66 for BE cases, 
64 for controls 
None  268 536 Any length Current smoker 
Smith et al 
(2009) a 
17
 
2009 Case 
control 
Australia GERD 
controls 
58.2 for BE 
cases, 53.5 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
 285 1350 Any length Former smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Smith et al 
(2009) b 
17
 
2009 Case 
control 
Australia GERD 
controls 
58.2 for BE 
cases, 53.5 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
 285 1350 Any length Current smoker 
Smith et al 
(2009) c 
17
 
2009 Case 
control 
Australia Non-GERD 
controls 
58.2 for BE 
cases, 57.9 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
Age and 
gender 
285 1350 Any length Former smoker 
Smith et al 
(2009) d 
17
 
2009 Case 
control 
Australia Non-GERD 
controls 
58.2 for BE 
cases, 57.9 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
Age and 
gender 
285 1350 Any length Current smoker 
Smith et al 
(2009) e 
17
 
2009 Case 
control 
Australia Non-GERD 
controls 
58.2 for BE 
cases, 57.9 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
Age and 
gender 
285 1350 Any length < 5 pack years 
Smith et al 
(2009) f 
17
 
2009 Case 
control 
Australia GERD 
controls 
58.2 for BE 
cases, 57.9 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
Age and 
gender 
285 1350 Any length < 5 pack years 
Smith et al 
(2009) g 
17
 
2009 Case 
control 
Australia Non-GERD 
controls 
58.2 for BE 
cases, 57.9 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
Age and 
gender 
285 1350 Any length ≥ 30 pack years 
Smith et al 
(2009) h 
17
 
2009 Case 
control 
Australia GERD 
controls 
58.2 for BE 
cases, 57.9 for 
controls 
Age, gender, education, current BMI, mean alcohol consumption, 
frequency of aspirin use in the 5 years before diagnosis, frequency of 
gastroesophageal reflux symptoms 10 years before diagnosis 
Age and 
gender 
285 1350 Any length ≥ 30 pack years 
Solaymani-
Dodaran et al 
(2004) a 
22
 
2004 Cross-
sectional 
UK GERD 
controls 
 None Age, gender, 
GP practice 
1677 27813 Any length Ever smoker 
Solaymani-
Dodaran et al 
(2004) b 
22
 
2004 Cross-
sectional 
UK GERD 
controls 
 None Age, gender, 
GP practice 
1677 27813 Any length Current smoker 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Solaymani-
Dodaran et al 
(2004) c 
22
 
2004 Cross-
sectional 
UK GERD 
controls 
 None Age, gender, 
GP practice 
1677 27813 Any length Former smoker 
Solaymani-
Dodaran et al 
(2004) d 
22
 
2004 Cross-
sectional 
UK GERD 
controls 
 None Age, gender, 
GP practice 
1677 27813 Any length Current smoker 
Solaymani-
Dodaran et al 
(2004) e 
22
 
2004 Cross-
sectional 
UK Non-GERD 
controls 
 None Age, gender, 
GP practice 
1677 27813 Any length Ever smoker 
 
Solaymani-
Dodaran et al 
(2004) f 
22
 
2004 Cross-
sectional 
UK Non-GERD 
controls 
 None Age, gender, 
GP practice 
1677 27813 Any length Current smoker 
Solaymani-
Dodaran et al 
(2004) g 
22
 
2004 Cross-
sectional 
UK Non-GERD 
controls 
 None Age, gender, 
GP practice 
1677 27813 Any length Former smoker 
Steevens et al 
(2010) a 
65
 
2010 Cohort The 
Netherlands 
Non-GERD 
controls 
61.1 for BE 
cases, 61.3 for 
controls 
None  370 4736 Any length Ever smoker 
Steevens et al 
(2010) b 
65
 
2010 Cohort The 
Netherlands 
Non-GERD 
controls 
61.1 for BE 
cases, 61.3 for 
controls 
Age, alcohol consumption, and BMI  370 4736 Any length Former smoker 
Steevens et al 
(2010) c 
65
 
2010 Cohort The 
Netherlands 
Non-GERD 
controls 
61.1 for BE 
cases, 61.3 for 
controls 
Age, alcohol consumption, and BMI  370 4736 Any length Current smoker 
Steevens et al 
(2010) d 
65
 
2010 Cohort The 
Netherlands 
Non-GERD 
controls 
61.1 for BE 
cases, 61.3 for 
controls 
Age, alcohol consumption, and BMI  370 4736 Any length < 20 pack years 
  
Authors 
 
 
Year 
 
 
Study 
Type 
 
 
Country 
 
 
Controls 
 
 
Mean Age 
 
 
Adjusted Variables 
 
 
 
Case-
control 
matching 
 
 
 
Number 
of Cases 
 
 
 
Total Size 
 
 
 
Length of 
BE 
 
 
Cigarette 
smoking 
exposure 
Steevens et al 
(2010) e 
65
 
2010 Cohort The 
Netherlands 
Non-GERD 
controls 
61.1 for BE 
cases, 61.3 for 
controls 
Age, alcohol consumption, and BMI  370 4736 Any length ≥ 40 pack years 
 
Tseng et al 
(2008) 
66
 
2008 Cross-
sectional 
Taiwan Non-GERD 
controls 
61.6 for BE 
cases, 51.7 for 
controls 
None  12 19812 Any length Current smoker 
Veugelers et al 
(2006) a 
67
 
2006 Case 
control 
Canada GERD 
controls 
59 for BE cases, 
55 for controls 
None  130 431 Any length Ever smoker 
Veugelers et al 
(2006) b 
67
 
2006 Case 
control 
Canada Non-GERD 
controls 
59 for BE cases, 
57 for controls 
None Age and 
gender 
130 431 Any length Ever smoker 
Veugelers et al 
(2006) c 
67
 
2006 Case 
control 
Canada Non-GERD 
controls 
59 for BE cases, 
57 for controls 
None Age and 
gender 
130 431 Any length < 5000 lifetime 
packs of 
cigarettes 
Veugelers et al 
(2006) d 
67
 
2006 Case 
control 
Canada Non-GERD 
controls 
59 for BE cases, 
57 for controls 
None Age and 
gender 
130 431 Any length ≥ 5000 lifetime 
packs of 
cigarettes 
 
Abbreviations: BE, Barrett’s esophagus; BMI, body mass index; GERD, gastroesophageal reflux disease; GI, gastrointestinal; LSBE, long segment Barrett's esophagus; NSAIDs, non-steroidal anti-inflammatory drugs; SSBE, short segment Barrett's 
esophagus. 
 
 
 
 Table 2: Meta-Analysis by Different Study characteristics 
 
 
Non-GERD controls (including population-based 
controls) 
Population-based controls GERD controls 
Study Characteristic 
Studies, 
n 
OR (95% CI) Pdifference I
2
, % 
 
Pheterogeneity 
 
Studies, 
n 
OR (95% CI) Pdifference I
2
, % 
 
Pheterogeneity 
 
Studies, 
n 
OR (95% CI) Pdifference I
2
, % 
 
Pheterogeneity 
 
Smoking exposure                
Ever smokers 13 1.44 (1.20, 1.74) <0.001 62 0.002 10 1.42 (1.15, 1.76) 0.001 61 0.006 8 1.18 (0.75, 1.86) 0.474 86 <0.001 
Current smokers 26 1.33 (1.14, 1.56) <0.001 59 <0.001 17 1.22 (1.02, 1.45) 0.030 59 0.001 15 1.52 (1.31, 1.77) <0.001 0 0.513 
Former smokers 9 1.51 (1.21, 1.88) <0.001 61 0.009 8 1.57 (1.21, 2.05) 0.001 63 0.008 4 1.39 (1.06, 1.81) 0.016 45 0.142 
Adjustment for 
confounders 
               
Adjustment for any 
confounders 
7 1.90 (1.35, 2.68) <0.001 71 0.002 4 1.96 (1.41, 2.73) <0.001 42 0.162 3 1.96 (1.05, 3.64) 0.034 79 0.009 
Adjustment for measures of 
obesity 
6 1.72 (1.26, 2.35) 0.001 66 0.01 4 1.96 (1.41, 2.73) <0.001 42 0.162 - - - - - 
  
Non-GERD controls (including population-based 
controls) 
Population-based controls GERD controls 
Adjustment for age and 
gender 
5 1.91 (1.46, 2.51) <0.001 22 0.318 4 1.96 (1.41, 2.73) <0.001 42 0.162 2 1.46 (0.99, 2.15) 0.057 57 0.128 
Study Characteristic 
Studies, 
n 
OR (95% CI) Pdifference I
2
, % 
 
Pheterogeneity 
 
Studies, 
n 
OR (95% CI) Pdifference I
2
, % 
 
Pheterogeneity 
 
Studies, 
n 
OR (95% CI) Pdifference I
2
, % 
 
Pheterogeneity 
 
Study design                
Case control 10 1.68 (1.28, 2.21) <0.001 59 0.009 - - - - - - - - - - 
Cohort 2 1.20 (1.05, 1.37) 0.008 0 0.935 - - - - - - - - - - 
Length of BE                
LSBE 3 1.57 (0.96, 2.57) 0.074 69 0.04 3 1.57 (0.96, 2.57) 0.074 69 0.04 - - - - - 
Continent                
Europe 5 1.44 (1.05, 1.99) 0.025 54 0.069 5 1.29 (0.98, 1.70) 0.071 59 0.045 3 0.84 (0.34, 2.09) 0.706 90 <0.001 
North America 6 1.45 (1.09, 1.94) 0.012 56 0.013 4 1.42 (1.04, 1.94) 0.027 47 .128 5 1.40 (0.91, 2.16) 0.123 74 0.005 
 
 
 Abbreviations: BE, Barrett’s esophagus; CI, confidence interval; GERD, gastroesophageal reflux disease; LSBE, long segment Barrett's esophagus; OR, odds ratio; SSBE, short segment Barrett's esophagus. 
Table 3: Meta-Analysis by Pack-Years Smoked 
 
Pack-year exposure Studies, n OR (95% CI) Pdifference I
2
, % Pheterogeneity 
Lowest pack-years 10 1.41 (1.22, 1.63) <0.001 0.00 0.490 
Highest pack-years 10 1.53 (1.27, 1.84) <0.001 26.87 0.197 
 
 
Abbreviations: OR, odds ratio; CI, confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study Selection Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BE, Barrett’s esophagus; SIM, specialized intestinal metaplasia 
 
Additional records identified 
through reference lists 
(n = 0) 
Records identified through 
database searching 
(n = 811) 
Records screened 
(n = 811) 
Records after duplicates removed 
(n = 811) 
Citations excluded via title and 
abstract (not related to BE and 
smoking) 
(n = 751) 
Full-text articles excluded due to not 
meeting inclusion criteria   
 (n = 21) 
 
• BE not confirmed histologically as 
SIM (n=5) 
• Risk estimate not reported or unable 
to be calculated (n=2) 
• Did not use a non-BE control group 
(n=1) 
• More recent data available (n=1) 
• Review article (n=12) 
Full-text articles assessed 
for eligibility 
(n = 60 ) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 39) 
Figure 2: Meta-Analysis of the Association between Ever Smoking and BE, BE Patients 
versus Non-GERD Controls 
 
Test for heterogeneity I
2
=61.73%, p=0.002. Each study is shown by an odds ratio 
estimate with the corresponding 95% confidence interval. 
Abbreviations: BE, Barrett’s esophagus; GERD, gastroesophageal reflux disease. 
 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Anderson et al (2007) a 1.04 0.72 1.51 0.836
Casson et al (2006) b 0.97 0.54 1.74 0.918
Edelstein et al (2007) a 2.10 1.41 3.12 0.000
Ferrandez et al (2006) c 2.06 1.27 3.34 0.003
Ibiebele et al (2011) 2.53 1.48 4.33 0.001
Jacobson et al (2011) a 1.20 1.02 1.41 0.027
Johansson et al (2007) a 1.80 0.72 4.51 0.210
Johansson et al (2007) b 3.30 1.10 9.90 0.033
Kubo et al (2009) 2c 1.40 0.98 2.00 0.063
Rubenstein et al (2008) b 6.30 1.89 20.94 0.003
Solaymani-Dodaran et al (2004) e 1.01 0.73 1.39 0.952
Steevens et al (2010) a 1.19 0.95 1.50 0.135
Veugelers et al (2006) b 1.20 0.70 2.04 0.502
1.44 1.20 1.74 0.000
0.01 0.1 1 10 100
Protective Harmful
Figure 3: Meta-Analysis of the Association between Ever Smoking and BE, BE Patients 
versus GERD Controls 
 
 Test for heterogeneity I
2
=86.00%, p<0.001. Each study is shown by an odds ratio 
estimate with the corresponding 95% confidence interval. 
Abbreviations: BE, Barrett’s esophagus; GERD, gastroesophageal reflux disease. 
 
 
 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Casson et al (2006) a 0.95 0.56 1.62 0.851
di Martino et al (2007) 1.53 0.93 2.52 0.094
Edelstein et al (2009) a 1.80 1.22 2.65 0.003
Kubo et al (2009) 2a 1.21 0.87 1.69 0.265
Olliver et al (2005) 1.00 0.48 2.09 1.000
Rubenstein et al (2008) a 6.40 2.18 18.81 0.001
Solaymani-Dodaran et al (2004) a 0.41 0.29 0.58 0.000
Veugelers et al (2006) a 0.87 0.53 1.43 0.585
1.18 0.75 1.86 0.474
0.01 0.1 1 10 100
Protective Harmful
CHAPTER	4	
 
BARRETT’S ESOPHAGUS AND 
THE RISK OF COLONIC TUMORS 
 
  
INTRODUCTION 
Barrett’s esophagus (BE) is a premalignant condition associated with esophageal 
adenocarcinoma.
1,2
 It involves the replacement of the normal squamous esophageal 
lining by specialized or intestinal columnar epithelium.
3,4
 In North America, BE is 
diagnosed when endoscopically observed columnar metaplasia is confirmed to contain 
specialized intestinal epithelia (characterized by the presence of goblet cells) on 
histological examination.
5
 
 
The possibility of an association between BE and an increased risk of colonic tumors was 
first raised by Sontaget al.
6
 in 1985. This is a clinically significant question because if a 
relationship is found, it carries implications in terms of screening BE patients for 
colorectal cancer (CRC). Since then, several studies have reported conflicting results, 
and the association is not well established. A systematic review in 1995
7
 showed a 
strong association; however, we questioned the authors’ methodology, including the 
use of a synthetic control group constructed by the authors, which appears to have 
been used in calculating the risk estimates for the studies analyzed. In addition, several 
new studies have been published since the time of the last systematic review reporting 
the prevalence of colonic tumors in patients with BE and therefore we considered it 
appropriate to perform a systematic review that also incorporated these studies. 
 
Our aim was to perform a meta-analysis combining the results of studies reporting the 
prevalence of colonic tumors in BE vs. controls, and thus provide a quantitative 
estimate of the risk of colonic tumors associated with BE. 
 
MATERIALS AND METHODS 
Study protocol 
We followed the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) 
guidelines,
8
 where possible, in performing our systematic review. A systematic search 
was performed by two reviewers (J.A. and M.T.) through Medline (1950 – present), 
PubMed (1950 – present), Embase (1947 – present), and Current Contents Connect 
(1998 – present) through to 7 October 2012, to identify relevant articles. The search 
used the terms "Barrett’s Esophagus" or "Barrett's Esophagus" and "colorectal cancer" 
or "colon cancer" or "rectal cancer" or "colonic tumors" or "colonic tumors" or "colonic 
neoplasms", which were searched as text word and as exploded medical subject 
headings where possible. The reference lists of relevant articles were also searched for 
appropriate studies. No language restrictions were used in either the search or study 
selection. A search for unpublished literature was not performed. 
 
Study selection 
We included studies that met the following inclusion criteria: (i) the study examined the 
prevalence of either benign (adenomas) or malignant (CRC) colonic tumors, or both, in 
BE patients and controls; (ii) the cases were patients diagnosed with BE and the controls 
were patients without BE; (iii) the risk point estimate was reported as an odds ratio 
(OR), or the data were presented such that an OR could be calculated; (iv) the 
95%confidence interval (CI) was reported, or the data were presented such that the CI 
could be calculated; (v) an internal comparison was used when calculating the risk 
estimate. We excluded studies that did not meet the inclusion criteria. Specifically, four 
studies
9-12
 were excluded as they included patients with esophageal adenocarcinoma to 
serve as either the cases or controls;three studies
13–15
 were excluded as they used an 
external comparator group and standardized incidence ratios; and one study
16
 was 
excluded as it used an external comparator group made up of groups of patients from 
previous studies. Studies were included or exclusion following consensus among three 
authors (J.A., M.T. and G.E.). 
 
Data extraction 
We performed the data extraction via a standardized data extraction form, collecting 
information on the publication year, study design, number of cases, number of controls, 
total sample size, temporal direction, population type, country, continent, economic 
development, case–control matching, mean age, number of adjusted variables, the risk 
estimates or data used to calculate the risk estimates, CIs or data used to calculate CIs, 
and the type of colonic tumor investigated (benign or malignant). Quality of the studies 
was not assessed and authors were not contacted for missing data. Adjusted ratios 
were extracted in preference to non-adjusted ratios; however, where ratios were not 
provided, unadjusted ORs and CIs were calculated. Where more than one adjusted ratio 
was reported, the ratio with the highest number of adjusted variables was selected. 
Where multiple risk estimates were available in the same study, for example, studies 
providing risk estimates for both malignant and benign tumors, they were included as 
separate risk estimates. Where studies provided only the risk ratio (RR) or hazard ratio 
(HR), we assumed that the RR or HR would be similar to the OR and thus the RRs and 
HRs provided were combined with the provided or calculated ORs. 
 
Statistical analysis 
We calculated pooled odds ratios and 95% confidence intervals for the effect of BE on 
the risk of any colonic tumors, as well as on benign colonic tumors and CRC, using a 
random-effects model.
17
 For the relationship between BE and any colonic tumors, we 
performed subgroup analyses based on studies which adjusted for any variables and 
specifically for the important confounder of body mass index (BMI), as well as subgroup 
analyses by temporal study direction (prospective vs. retrospective). We also analyzed 
the effect of the four
18–21 
studies included in our analysis which were in abstract form, 
and for comparison, also performed an analysis of the three studies
13–15 
which were 
excluded based on their use of an external comparator group. 
 
Heterogeneity was tested with Cochran’s Q statistic, with P < 0.10 indicating 
heterogeneity, and quantified the degree of heterogeneity using the I
2
 statistic, which 
represents the percentage of the total variability across studies, which is due to 
heterogeneity. I
2
 values of 25%, 50% and 75% corresponded to low, moderate and high 
degrees of heterogeneity respectively.
22
 Publication bias was quantified using the 
Egger’s regression model.
23
 All analyses were performed with Comprehensive Meta-
analysis (version 2.0). 
 
RESULTS 
Study characteristics 
From 1351 studies initially identified, 11
6,18–21,24–29 
met our inclusion criteria (Figure 1), 
of which four
18–21 
were abstracts. Selected characteristics of the included studies are 
presented in Table 1. The studies were all conducted in developed Western countries, 
with five studies examining European populations, and the remaining six studies 
examining North American populations. In terms of study design, one study was a 
prospective cohort study, and the remainder were retrospective studies. Sample sizes 
ranged from 96 to 15 093, and BE cases ranged from 32 to 1677. Overall, there were 
2580 BE patients and 27 272 participants. 
 
Any colonic tumors 
Eleven studies
6,18–21,24–29 
comprising of 2580 BE cases, reported an association between 
colonic tumors (either benign adenomas or CRC) and BE and were included in the 
analysis. We found an increased risk of colonic tumors in patients with BE, with pooled 
OR of 1.96 (95% CI, 1.56–2.46) (Figure 2). There was low heterogeneity, which was not 
statistically significant (I
2
 = 15%, P = 0.295). There was no publication bias (P = 0.520), 
and this was depicted visually on a funnel plot in Figure 3.  
 
We performed sensitivity analyses to assess whether adjustment for confounding 
variables changed the overall risk estimate. When looking at the five studies
19,24,25,28,29 
which adjusted for any variables, the risk of colonic tumors was 1.91 (95% CI, 1.48–
2.46), with no heterogeneity (I
2
 = 0%, P = 0.591). The six studies
6,18,20,21,27 
that did not 
adjust for any variables showed a risk of colonic tumors of 2.05 (95% CI, 1.29–3.26), 
with moderate heterogeneity, which was not statistically significant (I
2
 = 45%, P = 
0.103). 
 
The risk of colonic tumors calculated from the two studies
28,29 
which adjusted for BMI 
was statistically significant (OR 1.89; 95% CI, 1.30–2.76), while that calculated from the 
remaining ten studies, which did not adjust for BMI, was 2.02 (95% CI, 1.51–2.70), with 
moderate heterogeneity, which was not statistically significant (I
2
 = 34%, P = 0.161). 
 
When analyzing the ten retrospective studies,
6,18– 21,24–28
 the OR was 2.01 (95% CI, 1.58–
2.54), with low heterogeneity, which was not statistically significant (I
2
 = 17%, P = 
0.275). The only prospective cohort study had a risk estimate of 1.23 (95% CI, 0.44-
3.43). The pooled risk estimate after removing the four studies
18–21 
in abstract form was 
1.91 (95% CI, 1.34–2.70). There was moderate heterogeneity, which was not statistically 
significant (I
2
 = 34%, P = 0.161). 
 
The meta-analysis including the three excluded studies
13–15 
which used an external 
comparator group yielded a positive association with an OR of 1.67 (95% CI, 1.35– 2.07), 
with moderate heterogeneity (I
2
 = 50%, P = 0.013). The risk estimate calculated from 
only the three excluded studies
13–15 
was not significant (OR: 1.13, 95% CI, 0.63–2.02). 
There was a high degree of heterogeneity (I
2
 = 84%, P = 0.002). 
 
Benign colonic tumors 
Seven studies
6,18,21,24–27
 comprising of 361 BE cases and a total of 2568 individuals 
reported an association between benign colonic tumors and BE and were included in 
the benign colonic tumors meta-analysis. There was an increased risk of benign colonic 
tumors in patients with BE, with pooled OR of 1.69 (95% CI, 1.20–2.39) (Figure 4). We 
found low, statistically insignificant heterogeneity (I
2
 = 13%, P = 0.449). 
 
Colorectal Cancer 
Six studies
6,19,24,27–29
 comprising of 2321 BE cases and 25 793 individuals were included 
in the meta-analysis for CRC. We found an increased risk of CRC in patients with BE, 
with pooled OR of 1.90 (95% CI, 1.35–2.67) (Figure 5). There was no heterogeneity (I
2
 = 
0%, P = 0.452). 
 
DISCUSSION 
The meta-analyses showed a statistically significant positive relationship between BE 
and colonic tumors. This association was stronger for CRC than for benign tumors, 
although an exact mechanism explaining the association between BE and colonic 
tumors has not yet been established. 
 
A previous systematic review and meta-analysis by Howden and Hornung
7
 found a 
strong association between BE with specialized columnar epithelium and CRC, with an 
OR of 8.71. We questioned these authors’ use of a ‘comparison cohort’, which was 
constructed ‘from previously published studies of colorectal cancer screening in the 
general population’. In addition, the ORs used in the meta-analysis were not the ORs 
which were published in the original studies, and we were unsure as to how these 
numbers were obtained. In some instances, the ORs used by Howden and Hornung
7
 
were larger than the ORs published in the original studies by a factor of four to five. 
Since their publication, several investigators have disagreed with these large risk 
estimates.
16,30,31
 Our meta-analysis includes four studies 
18,25,28,29
 which were published 
subsequent to the Howden and Hornung
7
 study and therefore were not included in that 
study. Although like Howden and Hornung,
7
 we also find a statistically significant 
association between BE and colonic tumors, there are major issues with the 
interpretation of our results. 
 
First, only one of the studies included in the analysis, Solaymani-Dodaran et al,
29
 was a 
cohort study which looked at disease incidence over the study period, and it reported a 
positive but statistically insignificant association (OR: 1.23; 95% CI, 0.44–3.43). A 
sensitivity analysis excluding the Solaymani-Dodaran et al
29
 study yielded a risk estimate 
of 2.01 (95% CI, 1.58–2.54), with low heterogeneity. The remainder of the studies 
followed a retrospective study design and therefore were subject to the limitations and 
biases inherent in studies of that nature. This raises the question as to whether our 
overall positive result merely reflects biases inherent to retrospective studies, or 
whether it represents a real association. To ascertain whether a true association 
between BE and colonic tumors exists, there is a need for more large, prospective 
studies. The ideal study type would thus be a cohort study that recruited patients with 
BE and a control group representative of the general population with no colonic tumors 
at baseline, and observed the incidence of colonic tumors in the two groups over the 
study period. One problem with such a study would be the ethical issue of performing 
colonoscopies, which are invasive and carry risks of complications, on young 
asymptomatic individuals in the absence of any indications. Studies could, however, be 
carried out in patients aged over 50, in whom colonoscopies are recommended as a 
screening tool in many countries, including the USA.
32,33 
Prospective cohort studies 
would also be able to establish the existence of a temporal relationship, should one 
exist, between BE and colonic tumors, which would then have implications for 
screening. 
 
Our study was also subject to the likely presence of confounders in the individual 
studies. While we used the adjusted ORs where available, six of the eleven studies did 
not adjust for confounders, or did not state if such adjustments had been made. This 
raises the possibility that any observed association could be due to confounders that 
have not been adjusted for. In the subgroup of four studies that reported adjustments 
for possible confounders, we still found a significant association between BE and colonic 
tumors, with no significant change from the unadjusted result. However, of those 
studies that used adjusted ORs, only two studies adjusted for BMI, which is known to be 
a risk factor for both BE,
34
 and CRC,
35,36
 although the strength of the association 
between BMI and CRC varied with gender and cancer site in both Moghaddam et al
35
 
and Larsson et al.
36
 Additionally, some studies
37,38 
found the association of BMI with BE 
to be insignificant when adjusting for waist-to-hip ratio or waist circumference, which 
suggests that this association is driven mostly by central adiposity. Our subgroup 
analysis of the studies that adjusted for BMI (OR: 1.89) vs. those that did not adjust for 
BMI (OR: 1.80) did not show any appreciable difference. Solaymani-Dodaran et al,
29
 the 
only prospective cohort study in our meta-analysis, did not find a significant association 
between BE and CRC, but they reported a number of different risk estimates after 
adjusting for different factors. The risk estimate that included BMI was not significantly 
different from the risk estimate that excluded BMI, with the BMI adjusted risk at 1.23 
(95% CI, 0.44–3.43), and the non-BMI adjusted risk at 1.14 (95% CI, 0.41 3.18), which 
suggests that in their study, adjustment for BMI did not play a significant role in the risk 
estimate. 
 
There may also exist a referral or diagnostic bias with respect to BE and colonic tumors. 
This arises as both are gastrointestinal disorders and may be subject to investigation by 
the same physician upon the patient presenting with nonspecific gastrointestinal 
symptoms and signs such as anemia, which may warrant both upper and lower 
gastrointestinal endoscopies. One study by Murphy et al,
15
 which looked at the risk of 
CRC associated with BE but was excluded from our analysis because it did not use an 
internal comparator group, found that the standardized incidence ratio of CRC rose 
progressively as the follow-up period approached the time of BE diagnosis, thus raising 
the possibility of diagnostic bias. 
 
Even though we found no statistical heterogeneity in our meta-analyses, studies with 
differing designs and methodologies were included in the analysis. Specifically, we 
looked at one cohort study and ten retrospective studies, with four of the studies being 
in the form of abstracts. There existed also differences in the control groups between 
studies. Some of the patients were asymptomatic, while others were being investigated 
for gastrointestinal symptoms related to irritable bowel syndrome and even rectal 
bleeding. This may impact the risk estimates and add to the diagnostic bias discussed 
above, as well as contribute to heterogeneity.  
 
Additionally, our meta-analysis only comprised eleven studies, with the subgroup 
analyses of CRC and benign adenomas comprising six and seven studies respectively. All 
but one of the studies were retrospective in nature. Adjusted ORs were only available in 
five studies, and of those, only two adjusted for the confounder of BMI. For 
comparison, we performed an analysis based on the three studies
13–15 
which used an 
external comparator group. The studies reported conflicting results, with de Jonge et 
al
14
 reporting a positive, statistically significant association, and neither Murphy et 
al.15nor Cook et al
13
 finding an association. The overall pooled risk estimate was 
positive, but not statistically significant. This analysis is only based on only three studies 
which reported conflicting results, so while it is difficult to make a meaningful definitive 
comment on the impact their exclusion had on our results, it does not appear to have 
greatly influenced our result. The analysis with these studies included yielded a risk 
estimate of 1.67, which, while lower than the risk estimate of 1.96 obtained with the 
studies excluded, is still positive and still statistically significant. 
 
Our analysis included four studies which were published in abstract form, and to see if 
these had a significant impact on our overall results, we performed a subgroup analysis 
excluding the abstracts. No appreciable difference was found when removing these 
studies from the pooled risk estimate for any colonic tumors (OR: 1.91 with the 
abstracts removed vs. OR: 1.96), with the results maintaining statistical significance. 
This suggests that the abstracts did not have a large impact on the overall results. 
 
Notwithstanding the current lack of an established mechanism to explain the 
relationship between BE and colonic tumors, the existence of a positive association 
between the two as ascertained by our meta-analysis warrants a call for more large 
cohort studies to elucidate whether the relationship is a real one and not a result of 
bias. Should the association then be shown to be real, this discovery would carry a 
number of important implications. First, an established association will warrant a search 
for common genetic or environmental risk factors as well as more studies in basic 
science to establish a mechanism for and thus provide a better understanding of the 
association. Secondly, it will raise the important clinical question as to whether BE 
patients should be regularly screened for CRC, which several investigators
19, 24, 25 
have 
considered unwarranted due to inconclusive data, a view which we agree with at 
present. The CRC risk estimate in our study, 1.88 (95% CI, 1.32–2.68), is comparable to 
the increased risk of CRC in first degree relatives of patients with CRC of 2.24 (95% CI, 
2.06–2.43), as reported in a recent meta-analysis by Butterworth et al.
39
 Most of the 
studies included in that meta-analysis reported risk estimates between 1.5 and 4, which 
again is comparable to the association we found between BE and CRC. In addition, a 
more recent Italian study Castiglione et al,
40
 found the risk of CRC in first degree 
relatives of CRC patients to be 1.53 (95% CI, 1.27–1.83), also comparable to our risk 
estimate. If the risk estimates for CRC in patients with BE reflects a real relationship, this 
risk for CRC is similar to that found in first degree relatives of patients with CRC, and 
serious consideration may need to be given in the future to screening BE patients for 
CRC. 
 
Our study had a number of strengths. The MOOSE guidelines were followed where 
possible. We performed a thorough search through four databases with no language 
restrictions. Studies using external comparators were excluded. The use of an internal 
control group is recognized as superior in terms of study design,
41–43
 and by excluding 
studies that used external comparators, we added statistical rigor to our analysis. 
Additionally, we observed no statistically significant heterogeneity in any of our 
analyses, and publication bias was not present. 
 
In summary, our results suggest that BE is associated with an increased risk of colonic 
tumors. The association was present for both benign and CRC, but was stronger for CRC. 
More prospective cohort studies adjusting for possible confounders are needed to 
further elucidate this relationship. At present, we recommend against screening BE 
patients for CRC due to the lack of robust prospective evidence supporting this 
association. 
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Table 1: Studies reporting prevalence of any colonic tumors in BE patients which were included in the Meta-analysis 
 
 
 
Authors 
 
 
Year 
 
 
Temporal 
Direction 
(prospective or 
retrospective 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
 
Case-control 
matching 
 
 
Number 
of Cases 
 
 
Total Size 
 
 
 
Colonic tumor 
investigated 
Cauvin et al.
24
 a 1995 Retrospective France BE patients Consecutive patients with symptoms 
suggestive of IBS 
 
Age, gender, family 
history of CRC, rectal 
bleeding 
None 104 641 Benign 
(adenomas) 
Cauvin et al.
24
 b 1995 Retrospective France BE patients Consecutive patients with symptoms 
suggestive of IBS 
 
Age, gender, family 
history of CRC, rectal 
bleeding 
None 104 641 Malignant 
Elli et al.
18
 2010  
Retrospective 
Italy BE patients Patients who underwent 
esophagogastroduodenoscopyand 
colonoscopy. 
Not stated NA NA 1018 Benign ( colon 
polyps 
Gerson et al.
25
 2002  
Retrospective 
USA BE patients free 
from GERD 
symptoms, who 
were undergoing 
sigmoidoscopy for 
CRC screening 
Patients free from GERD symptoms, 
who were undergoing sigmoidoscopy 
for CRC screening  
Age None 44 110 Benign (colon 
polyps) 
Laitakari et al.
26
 1995  
Retrospective 
Finland BE patients Patients referred to hospital for 
benign thyroid, inguinal hernia or 
hand surgery, who had been attending 
urological or vascular examinations 
None None 72 99 Benign 
(adenomas) 
Limburg et al.
19
 1994  
Retrospective 
USA BE patients Patients with peptic ulcer disease and 
gastric polyps 
Age, gender, time 
between first 
colonoscopy and 
esophagogastro-
duodenoscopy 
 175 8922  
Malignant (CRC at 
any site)  
Lyons et al.
20
 1993  
Retrospective 
USA  
BE patients 
Patients with gastroesophageal reflux 
with stricture 
None None 99 153 Both benign and 
malignant 
Robertson et 
al.
27
 a 
1989  
Retrospective 
UK BE patients Patients clinically diagnosed IBS None Age and gender 32 96 Benign (polyps 
and adenomas) 
  
Authors 
 
 
Year 
 
 
Temporal 
Direction 
(prospective or 
retrospective 
 
 
Country 
 
 
Cases 
 
 
Controls 
 
 
Adjusted Variables 
 
 
Case-control 
matching 
 
 
Number 
of Cases 
 
 
Total Size 
 
 
 
Colonic tumor 
investigated 
Robertson et 
al.
27
 b 
1989  
Retrospective 
UK BE patients Patients clinically diagnosed IBS None Age and gender 32 96 Malignant 
Robertson et 
al.
27
 c 
1989 Retrospective UK BE patients Patients clinically diagnosed IBS None Age and gender 32 96 Both benign 
(polyps and 
adenomas) and 
malignant 
Rothstein et al.
21
 1991 Retrospective USA BE patients Patients undergoing upper and lower 
endoscopic surveillance in the workup 
of an iron deficiency anemia 
None None 44 99 Benign polyps 
Siersema et al.
28
 
a 
2006 Retrospective USA BE patients Patients who had had undergone 
upper GI endoscopy 
within 14 days of the corresponding 
case 
Age, BMI, other 
malignancies, use of 
PPIs, use of 
aspirin/NSAIDS, alcohol 
consumption, smoking 
status 
Date of 
endoscopy 
268 536 Both benign and 
malignant 
Siersema et al.
28
 
b 
2006 Retrospective USA BE patients Patients who had had undergone 
upper GI endoscopy 
within 14 days of the corresponding 
case 
Age, BMI, other 
malignancies, use of 
PPIs, use of 
aspirin/NSAIDS, alcohol 
consumption, smoking 
status 
Date of 
endoscopy 
268 536 Malignant 
Solaymani-
Dodaranet al.
29
 
2004 Prospective UK BE patients Patients on the GP database with no 
restriction other than not having BE 
Age, gender, number of 
visits per year, 
smoking, alcohol and 
BMI 
Age, gender 
and GP practice 
1677 15 093 Malignant 
Sontag et al.
6
  a 1985 Retrospective USA BE patients Patients who underwent colonoscopy 
for occult blood in stool, weight loss, 
rectal bleeding, or abdominal pain 
None None 65 505 Benign 
Sontag et al.
 6
 b 1985 Retrospective USA BE patients Patients who underwent colonoscopy 
for occult blood in stool, weight loss, 
rectal bleeding, or abdominal pain 
None None 65 505 Malignant 
Sontag et al.
6
 c 1985 Retrospective USA BE patients Patients who underwent colonoscopy 
for occult blood in stool, weight loss, 
rectal bleeding, or abdominal pain 
None None 65 505 Both benign and 
malignant 
 
Abbreviations: BE, Barrett’s esophagus; IBS, irritable bowel syndrome; CRC, colorectal cancer; GERD, gastroesophageal reflux disease; GI, gastrointestinal; BMI, body mass index; PPI, proton pump inhibitor; NSAID, non-steroidal anti-inflammatory; GP, general 
practitioner; NA, not available. 
Figure 1: Study Selection Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BE, Barrett’s esophagus 
1543 citations identified via 
database search 
 38 Studies reviewed 
27 studies excluded (did not meet 
inclusion criteria) 
• studies included patients 
with esophageal 
adenocarcinoma to serve as 
either the cases or controls 
• risk estimate not reported 
or unable to be calculated 
• internal comparator not 
used 
1505 studies excluded (did 
not assess BE or colonic 
tumors) 
 
11 eligible studies included 
in meta-analysis 
Figure 2: Meta-Analysis of BE and any colonic tumours 
 
 
Abbreviations: BE, Barrett’s esophagus 
 
 
 
 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Cauvin et al (1995) a 1.40 0.71 2.75 0.329
Cauvin et al (1995) b 5.29 1.05 26.61 0.043
Elli et al (2010) 2.97 1.18 7.49 0.021
Gerson et al (2002) 2.90 1.01 8.35 0.049
Laitakari et al 1995) 0.73 0.27 1.97 0.535
Limburg et al (1994) 1.91 1.22 2.98 0.004
Lyons et al (1993) 2.74 1.31 5.73 0.007
Robertson et al (1989) c 6.78 1.66 27.71 0.008
Rothstein et al (1991) 1.35 0.60 3.03 0.467
Siersema et al (2006) a 2.02 1.35 3.03 0.001
Solaymani-Dodaran et al (2004) 1.23 0.44 3.43 0.693
Sontag et al (1985) c 2.08 1.22 3.54 0.007
1.96 1.56 2.46 0.000
0.1 0.2 0.5 1 2 5 10
Protective Harmful
Figure 3: Funnel plot to assess publication bias 
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Figure 4: Meta-Analysis of BE and benign colonic tumors 
 
 
 
Abbreviations: BE, Barrett’s esophagus 
 
 
 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Cauvin et al (1995) a 1.40 0.71 2.75 0.329
Elli et al (2010) 2.97 1.18 7.49 0.021
Gerson et al (2002) 2.90 1.01 8.35 0.049
Laitakari et al 1995) 0.73 0.27 1.97 0.535
Robertson et al (1989) a 3.77 0.84 16.91 0.083
Rothstein et al (1991) 1.35 0.60 3.03 0.467
Sontag et al (1985) a 1.73 0.96 3.11 0.067
1.69 1.20 2.39 0.003
0.1 0.2 0.5 1 2 5 10
Protective Harmful
Figure 5: Meta-Analysis of BE and malignant colonic tumors 
 
 
Abbreviations: BE, Barrett’s esophagus 
 
 
 
 
 
 
 
 
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Cauvin et al (1995) b 5.29 1.05 26.61 0.043
Limburg et al (1994) 1.91 1.22 2.98 0.004
Robertson et al (1989) b 15.31 0.77 305.10 0.074
Siersema et al (2006) b 1.00 0.20 5.00 1.000
Solaymani-Dodaran et al (2004) 1.23 0.44 3.43 0.693
Sontag et al (1985) b 1.92 0.91 4.07 0.088
1.90 1.35 2.67 0.000
0.1 0.2 0.5 1 2 5 10
Protective Harmful
CHAPTER	5	
 
SUMMARY AND CONCLUSIONS 
  
The purpose of the work contained within this thesis was to further expand on the knowledge of the 
epidemiology of Barrett's esophagus (BE). In particular, Chapters 2-4 contain meta-analyses which 
examine and quantify the association between BE and hiatal hernia, cigarette smoking, and colonic 
tumors, respectively. 
 
Hiatal hernia has a long and clinically well-established relationship with BE, however the relationship 
has not yet been quantified through a meta-analysis.  In conducting a meta-analysis on the topic, I 
have for the first time quantified the association and also found the relationship to be stronger for 
long segment BE than for short segment BE. Furthermore, it is usually assumed that the relationship 
between hiatal hernia and BE is due to hiatal hernia predisposing to reflux, which then damages the 
esophageal epithelium, resulting in BE.
1,2 
As part of our study, a subgroup analysis was performed by 
studies which adjusted for reflux. This showed that the relationship between hiatal hernia and BE 
remained even after adjusting for reflux, with an odds ration of 3.35 (95% CI, 2.25–4.39) for the 
association between hiatal hernia and any length of BE and 13.84 (95% CI, 5.19–36.89) for long 
segment BE. This finding of an  association between hiatal hernia and BE independent of reflux is an 
important one and supports the hypothesis that the relationship is a real one, rather than a result of 
confounding factors. 
 
Environmental factors such as smoking, although well established as risk factors for squamous cell 
carcinoma of the esophagus,
3
 have to date not been definitively implicated in the development of BE 
or adenocarcinoma. Although a recent pooled analysis of 5 case control studies from the 
International Barrett's and Esophageal Adenocarcinoma Consortium ("BEACON")
4
 finding a positive 
relationship between cigarette smoking and BE has been published, ours was the first meta-analysis 
of the relationship and included, in addition to the BEACON studies, a large number of other studies. 
Confirming the findings in the BEACON pooled analysis, we found a positive association between 
smoking and BE. Although we did not observe a convincing dose response - the odds ratios for the 
lowest pack-year and highest pack-year groups were 1.41 and 1.53, respectively, with overlapping 
confidence intervals - the positive association was observed across subgroup analyses. Furthermore, 
the relationship was stronger when adjusting for confounders such as obesity, age and gender. Our 
study was the largest to date on the topic and represents arguably the strongest evidence of a link 
between cigarette smoking and BE. It is also an exciting finding, because if the relationship is real, 
smoking represents one of the few known modifiable risk factors for BE, and this could therefore be 
important in counseling patients on reducing the risk of developing BE. 
 
An intriguing possibility is the association between BE and tumors of the colon, both benign and 
malignant. Although first raised in 1985,
5
 the issue remains unresolved despite a number of studies 
and an earlier meta-analysis
6
 published on the subject since then. Ours is the second meta-analysis 
studying the association and incorporates more recent studies published since the last meta-analysis 
was performed in 1995. We found a positive and statistically significant relationship between BE and 
colonic tumors. This relationship remained in the subgroup analyses which adjusted for confounding 
factors and specifically for body mass index, although only two studies constituted the latter group. 
The association was present for both benign and colorectal cancer (CRC), but was stronger for CRC. 
This potential association is significant clinically because if patients with BE are at increased risk of 
CRC, it raises the question of whether they should be screened earlier for CRC than is recommended 
for the general population. Despite our positive results, at present, we recommend against screening 
BE patients for CRC due to the lack of robust prospective evidence supporting this association. 
However, it will be interesting to observe the results of future prospective cohort studies adjusting 
for possible confounders.  
 
In summary, the three meta-analyses incorporated in this thesis examined and quantified, 
respectively, the association between BE and hiatal hernia, cigarette smoking, and colonic tumors. 
The results showed positive associations for the relationships studied. It is hoped that this work will 
contribute towards the existing body of knowledge on BE and its risk factors and associations.  
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